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Introduction
In the recent years it is emerged that peripheral arterial disease (PAD) has become a growing 
health problem in Western countries. This is a progressive manifestation of atherothrombotic 
vascular disease, which results into the narrowing of the blood vessels of the lower limbs and, 
as  final  consequence,  in  critical  leg  ischemia.  PAD  often  occurs  along  with  other 
cardiovascular  risk  factors,  including  diabetes  mellitus  (DM),  low-grade  inflammation, 
hypertension, and lipid disorders. Patients with DM have an increased risk of developing PAD, 
and that risk increases with the duration of DM. 
Diabetes mellitus is a metabolic disorder characterised by elevated glucose levels. People with 
type 1 diabetes have inadequate insulin production by pancreas islets, while type 2 diabetes is 
characterized  by  relative  insulin  deficiency  and  or  insulin  resistance.  In  particular, type  2 
diabetes is becoming more common, maybe because of an ageing population and the increasing 
prevalence of  obesity and sedentary lifestyles.  Moreover, there  is a growing population of 
patients  identified  with  insulin  resistance  (IR),  impaired  glucose  tolerance,  and  obesity, a 
pathological  condition  known  as  “metabolic  syndrome”,  which  presents  increased 
cardiovascular risk. 
Atherosclerosis, which is the earliest symptom, is a dynamic and progressive disease arising 
from the combination of endothelial dysfunction and inflammation. Endothelial dysfunction is 
a broad term that implies diminished production or availability of nitric oxide (NO) and/or an 
imbalance in the relative contribution of endothelium-derived relaxing factors,  in particular 
prostacyclin. The secretion of both these agents is considerably reduced in association with the 
major risks of atherosclerosis, especially hyperglycaemia and diabetes.  Moreover, it has been 
observed  a  reduced  vascular  repair  in  response  to  wound  healing  and  reduced  collateral 
formation in response to ischemia. 
Neovascularization  does  not  only  rely  on  proliferation  of  local  endothelial  cells  but  also 
involves bone marrow-derived stem cells, referred to as endothelial progenitor cells, since they 
exhibit endothelial surface markers and properties.  They can promote postnatal vasculogenesis 
by homing to, differentiating, proliferating and incorporating into new vessels.  Consequently, 
EPCs are critical to endothelium maintenance and repair and their dysfunction contribute to 
vascular disease. 
Nitric  oxide  itself  is  involved in neovascularization.  In  fact,  NO produced by eNOS, the 
endothelial  isoform  of   nitric  oxide  synthase  (NOS),  effects  endothelial  migration  and 
1
proliferation. 
The aim of this research has been the study of EPCs and their functionality under physiologic 
condition,  considering  their  role  in  therapeutic  vasculogenesis.  Furthermore, it  has  been 
analyzed their function under pathological conditions. Thus, EPCs isolated from atherosclerotic 
and diabetic  patients  have been examined with  respect  to  proliferation,  differentiation and 
function.
Given  the  importance  of  NO in  angiogenesis  and  vasculogenesis,  it  has  been  studied  the 
expression of NOS isoforms, inducible NOS (iNOS), eNOS (endothelial NOS), and neuronal 
NOS (nNOS), comparing normal NOS pattern to that of patients affected with PAD.  
In  addition,  it  has  to  be  considered  the  correlation  between  endothelial  dysfunction  and 
enhanced levels of reactive oxidative species (ROS). In fact, the principal mechanism of ROS-
dependent endothelial impairment is  the inactivation of NO. As a result,  the expression of 
NADPH oxidase isoforms  (Nox1, Nox2 and Nox4) was investigated.         
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Chapter 1
Peripheral Arterial Disease
Peripheral arterial disease (PAD) is a common progressive manifestation of atherothrombotic 
vascular disease, resulting into the narrowing of the blood vessels of the lower limbs (1).  This 
atherosclerotic condition is very common in the western world, affecting more than 27 million 
people in North America and Europe, and this number is expected to increase with the aging 
population (2). It affects at least 10% of individuals, men and women equally, aged over 65 
years and 20% of those aged over 80 years (3). 
Albeit it is a common clinical malady, PAD is relatively unknown to the public, compared to 
heart disease, which is taught widely in health education programs and raises many public 
health initiatives.  Even in the absence of  a  history of  myocardial  infarction or  stroke,  the 
relative risk of death from cardiovascular causes in patients with PAD is about the same as in 
patients with coronary or cerebrovascular disease. Patients with critical leg ischemia, the most 
severe  form  of  PAD, face  an  annual  mortality  of  25%,  which  is  predominantly  due  to 
myocardial infarction and ischemic stroke (4).
In their  study, Caro et al  estimated the burden of cardiovascular  risk in term of mortality, 
morbidity and associated risk factors in patients with PAD (5). They compared the PAD cohort 
to those of people with a first diagnosis of myocardial infarction and stroke. It was evident that 
the mortality rate of PAD patients was higher compared to those who had an index myocardial 
infarction, but lower than those who had suffered from stroke. At the end of the follow-up 
period, half of the patients with PAD were alive, compared to about 60% of those belonging to 
the myocardial infarction group and 51% of those with stroke.    
As  expected,  risk factors  analyses  revealed that  men with  PAD were  more  likely  to have 
atherothrombotic complications, angina, myocardial infarction, stroke and death (6). Moreover, 
the risk of myocardial infarction was significantly increased in people aged over 65 years, 
especially  with  concomitant  angina,  diabetes  mellitus,  heart  failure  and  hypertension. 
Cardiovascular  risk  increase  in  PAD patients  depended  on  the  number  of  additional  risk 
factors, resulting in a “cumulative” cardiovascular risk, similarly to cardiac disease.  
However,   all  epidemiologic  cross-sectional  studies  show  that  in  the  general  population 
asymptomatic peripheral arterial occlusive disease (PAOD) is more common than symptomatic 
PAOD (7). As PAD progresses, patients start to feel pain due to the impaired blood flow, which 
causes decreased oxygen and nutrient supply in the distal tissue. This can further develop into 
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tissue ischemia, and consequently to skin ulceration and muscle damage.  In fact,  the most 
evident symptom in PAD patients is intermittent claudication (IC), indicating a blood supply 
deficiency in muscle during exercise. The prevalence of IC increases with age, affecting >5% 
of patients over 70, and its incidence in diabetic patients doubles or even triples (7). 
The asymptomatic PAD subjects remain however a high risk population, and those who are 
diagnosed PAD are less frequently under lipid-lowering therapy and antiplatelet  therapy in 
comparison to those with cardiovascular disease. This could be explained because of symptom 
variability. Approximately 36% of patients with PAD have symptoms, however, only one third 
of them reports symptoms to their physician and receives appropriate treatment (8). It becomes 
essential to screen patients, being symptom self-reporting unreliable.     
Diagnosis of PAD
Diagnosis of PAD is made by medical history, physical examination, and the measurement of 
ankle blood pressures using a Doppler ultrasound device. The ankle branchial index (ABI) is 
defined as the ratio of ankle pressure to the branchial systolic pressure. The ABI has been 
proven to be an effective for recognizing the disease in patients with or without symptoms. The 
reference range of ABI is 0,91 to 1,4. An ABI ≤0.9 corresponds to a diagnosis of PAD, and it is 
associated with increased fatal and nonfatal coronary artery disease, and stroke. The lower the 
ABI is, the disease gets more hemodinamically severe (9).   
ABI rate Clinical 
0.9> Normal
0.7-0.9 Mild claudication
0.5-0.7 Moderate claudication
0.4-0.5 Severe claudication
<0.4 Rest pain, nonhealing ulcers
Table 1. Ankle-brachial index and corresponding symptomatology
It has also been found that individuals with an ABI >1.40 have mortality rates similar to those 
who have an ABI  ≤0.9. These patients have noncompliant vessels secondary to pathological 
processes  involving  vascular  fibrosis  and calcification;  they  tend to  have greater  coronary 
artery calcium (10). Some have suggested a tighter range for normal ABI, since individuals 
with  an  ABI  between  0.9  and  1.00  manifest  more  ischemic  leg  pain  (11),  subclinical 
atherosclerosis, and are in greater risk for cardiovascular disease (12). Although the ABI is an 
excellent screening test, there is only a modest correlation between its value and the functional 
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limitation. For instance, an ABI of <0.5 is typically observed in patients with resting pain or 
tissue loss. On the other hand, a similar ABI can be discovered in an individual with only a 
modest  symptomatology  (13).  These  differences are  probably  due  to  the  heterogeneity  in 
collateral formations or skeletal muscle adaptation.
As described above, there is a substantial overlap between the pathogenesis of PAD and other 
forms of atherosclerotic disease, like coronary artery disease (CAD) and carotid disease. PAD 
and  CAD  share  several  risk  factors,  including  diabetes,  smoking,  hypertension,  insulin 
resistance,  low high-density  lipoprotein  levels,  elevated low-density  lipoprotein  levels,  and 
advanced age. Approximately 70% of PAD cases (as defined by ABI) can be attributed to these 
risk  factors  (14),  somewhat  higher  than  the  corresponding  estimates  for  CAD.  There  are 
evidences  that  some  of  these  risk  factors  have  proportionately  greater  effects  on  the 
development  of  PAD than  CAD.  For  instance,  diabetes  mellitus  (DM)  and  smoking  are 
particular strong risk factors (15).
In a study conducted by a Dutch group (16), the Limburg PAOD Study, a study population of 
more  than  2,000  people  selected  from  several  practice  centers  in  the  Netherlands  was 
examined. After a 7 year follow-up, the high incidence of intermittent claudication in patients 
who  were  asymptomatic  suggests  that  cessation  of  smoking  and  adequate  treatment  of 
hypertension and diabetes are the principal preventive objectives in PAOD patients.
Number and
combination of
risk factors
at baseline
Probability
(%)
of
overall
PAOD
Probability
(%)
of
asymptomatic
PAOD
Probability
(%)
of
symptomatic
PAOD
Reference probability 3 2 3
Age ≥65 years 8 5 1
Age ≥65 years and
hypertension
15 9 2
Age ≥65 years and smoking 18 10 6
Age ≥65 years and diabetes 18 10 5
Age ≥65 years, hypertension, 
and diabetes
28 16 9
Age ≥65 years, smoking,
 and hypertension
29 17 11
Age ≥65 years, smoking,
and diabetes
33 18 19
Age ≥65 years, smoking,
hypertension, and diabetes
47 27 31
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Table 2. Probability (%) of asymptomatic and symptomatic peripheral arterial occlusive disease (PAOD) according 
to the number and combination of the four most significant risk factors present at baseline*: Limburg PAOD 
Longitudinal Study, 1988–1997 (n = 2,327).
However, despite the evaluation of multiple risk factors, the progression of PAD seems to be 
highly variable, suggesting the presence of other determinants of the disease, and, in particular, 
genetic ones. 
Classification of Peripheral Arterial Disease and Clinical Manifestations
Various classification have been used to define the severity of PAD, of which the Fontaine and 
Rutherford classifications are widely used:
Fontaine Rutherford
stage Clinical Grade Category Clinical
I Asymptomatic 0 0 Asymptomatic
IIa Mild Claudication 1 Mild Claudication
IIb Moderate I 2 Moderate claudication
Severe claudication I 3 Severe claudication
III Ischemic rest pain II 4 Rest pain
III 5 Minor tissue loss
IV Ulceration/gangrene III 6 Major tissue loss
Tab. 3 Classification of peripheral arterial occlusive disease.  
Claudication, rest pain, and/or skin ulceration are the usual symptoms of PAD. The diagnosis 
of  intermittent  claudication  includes  pseudoclaudication  and  venous  claudication. 
Pseudoclaudication has a nonarterial etiology, its origin can be neurogenic or muscoloskeletal. 
It may lead to discomfort from spinal stenosis, compartment syndromes, venous congestion, or 
arthritis. It is symptomatic only in certain positional changes, such as standing. On the contrary, 
venus claudication causes a burning sensation while standing or walking.
Firstly, therapy in patients with PAD implies modifying risk factors and attempting to relieve 
symptoms of claudication with exercise or medicine or both. An antiplatelet and cholesterol 
lowering therapy is considered a basic approach to PAD treatment. Nevertheless, all patients 
who have rest pain, tissue loss, or significant lifestyle limiting disability, despite aggressive 
medical treatment should be considered eligible to revascularization. 
Invasive diagnostic angiography is reserved for patients in whom revascularization is planned 
or for those situations in which the results from noninvasive imaging are ambiguous (17). 
Complications  associated  with  catheter-based  angiography  are  related  to  vascular  access, 
catheter trauma (atheroembolism, vessel dissection, or perforation), or systemic complications 
associated  with  contrast  reactions  or  renal  toxicity.   Complications  associate  with 
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percutanueous transluminal coronary angioplasty (PTCA) are access-site events, amputation, 
and major bleeding. 
Endovascular procedures are indicated for individuals with a lifestyle limiting disability due to 
intermittent  claudication,  when  clinical  features  suggest  a  reasonable  likelihood  of 
symptomatic improvement with endovascular intervention. Atherosclerotic occlusive disease 
can affect different vascular beds, and in particular, the most affected ones in lower limbs are 
iliac arteries, femoropopliteal arteries, infrapopliteal arteries. Atherosclerotic occlusive disease 
is  two  to  five  times  more  frequent  in  femoropopliteal  arteries  than  in  iliac  arteries. 
Percutaneous angioplasty, however, is not always effective in treating femoropopliteal arteries. 
There are many factors that adversely affect the possible advantages of this  technique, like 
occlusion degree (especially if it is bigger than 10 cm), calcification, multiple-lesion segments, 
rest ischemia and a poor distal runoff. 
Infrapopliteal disease usually coexists with more proximal inflow disease and for patients who 
have claudication, revascularization of proximal inflow vessels is often sufficient to relieve 
symptoms. In contrast, patients with ischemic ulceration generally need to have flow restored 
to the foot to heal the lesion. The immediate and long-term results of arterial reconstruction for 
infrapopliteal  disease are  better  in  patients  who have claudication than in  those who have 
critical limb ischemia (CLI). Diabetic patients with CLI will more often have 3-vessel below-
knee  disease  and  may  also  have  ulceration  related  to  small-vessel  disease  that  will  not 
generally improve with revascularization.
For those patients who are not candidates for revascularization due to critical limb ischemia 
and for those who can be successfully revascularized but will have compromised limb function, 
amputation keeps to be considered as a primary therapeutic option (18).
Nevertheless,  a  comparative  study  between  patients  undergoing  angioplasty  and  those 
undergoing open surgery showed that, firstly, there is no difference in life quality of the two 
groups,   and  secondly, costs  associated  with  a  surgery-first  strategy  were  higher  than  for 
angioplasty. a percutaneous-intervention–first strategy was the treatment of choice in patients 
who are candidates for either surgery or endovascular intervention. 
Moreover,  there  has  been  much  interest  in  developing  an  agent  that  would  stimulate 
angiogenesis in patients who have CLI but do not have the option for revascularization. In 
order  to achieve this  goal,  initial  work has  progressed in the areas of genes that  code for 
various growth factors and the use of endothelial progenitor cells to stimulate angiogenesis.
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Chapter 2
Atherosclerosis and Endothelial Dysfunction
Atherosclerosis  is  a  dynamic  and  progressive  disease  arising  from  the  combination  of 
endothelial  dysfunction  and  inflammation.  It  develops  similarly  in  the  coronary, 
cerebrovascular, and peripheral vasculature systems; these vascular beds are interdependent, 
and subsequent disease progression are manifestations of the same process (2). Therefore, they 
are associated with the same clinical events as the disease process overlap.
The endothelium is a complex endocrine and paracrine organ, located between the wall of 
blood vessels and the blood stream (19). It senses mechanical stimuli, such as pressure and 
shear  stress,  and hormonal  stimuli,  such  as  vasoactive  substances.  In  response,  it  releases 
agents that regulate vasomotor function, trigger inflammatory processes, and affect hemostasis. 
Vascular homeostasis is maintained by a balance between endothelium-derived relaxing and 
contracting factors. Once this balance is disrupted, because of inflammatory and traditional 
cardiovascular risk factors, the vasculature becomes susceptible to atheroma formation.
Initiation of Inflammation and Atherosclerosis   
It  is now well accepted that  atherosclerosis is  a specific form of the chronic inflammatory 
process  resulting  from  interactions  between  plasma  lipoproteins,  cellular  components 
(monocytes/macrophages, T lymphocytes, endothelial cells and smooth muscle cells) and the 
arterial wall (20). The accumulation of lipid-loaded cells underlying the endothelium of large 
arteries,  namely, fatty  streaks  or  dots,  is  a  marker  of  early-stage  atherosclerotic  lesions. 
Numerous  studies  of  either  human  atherosclerotic  lesions  or  cholesterol-fed  animals  have 
shown that the lipid-loaded cells mainly originate from monocytes subsequently differentiated 
macrophages  (21).  These  macrophages  engulf  a  large  amount  of  lipids  deposited  in  the 
subintimal space and take the appearance of foamy structures, designated as foam cells. In this 
process it is involved  the up-regulation of  pattern recognition receptors, including scavenger 
receptors,  cell surface membrane proteins capable of binding and internalization of modified 
lipoproteins (22),  and toll-like receptors. 
Three major lipoproteins are often observed in the lesions and are considered to be atherogenic, 
at elevated plasma concentrations: low density lipoprotein (LDL); especially small dense LDL, 
remmant lipoproteins and lipoprotein (a) [Lp (a)] (23).
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These  atherogenic  lipoproteins,  once  deposited  in  the  intima,  are  subjected  to  chemical 
modifications, such as oxidation. While oxLDL is invariably associated with foam cells in the 
lesions  Lp (a),  though  it  is  present  in  the  lesions,  it  is  seldom associated  with  foam cell 
formation, tending to be associated with the extracellular matrix. 
In addition to foam cells, T lymphocytes are scattered around macrophages and foam cells. T 
cells  are  predominant  in  the  incipient  phase,  afterwards  they  are  gradually  surpassed  by 
monocyte infiltration in later stages (24). They actively participate to lesion progression, by 
releasing different cytokines, in addition to those derived from vascular cells. One of the most 
notable cytokines derived from T lymphocytes is interferon gamma (INF-γ), which has been 
shown to play diverse role in mediating foam cell formation, smooth muscle cell proliferation, 
and in regulating the production of matrix metalloproteinases, subsequently influencing plaque 
stability.   As  seen  in  cholesterol-fed  animals,  while  under  ordinary  circumstances  the 
endothelial monolayer in contact with flowing blood resists firm adhesion of leukocytes, soon 
after  initiating an  atherogenic  diet  electron microscopy reveals  attachment  of  mononuclear 
cells  to  the  endothelial  cells  that  line  the  intima,  the  innermost  layer  of  arteries  (25). 
Mononuclear cell adherence is triggered by a number of adhesion molecules on endothelial 
cells that are highly up-regulated by the elevation of the levels of atherogenic lipoproteins and 
cytokines  in  vitro.  One  endothelial–leukocyte  adhesion  molecule,  vascular  cell  adhesion 
molecule-1  (VCAM-1),  has  emerged  as  a  particularly  attractive  candidate  for  the  early 
adhesion of mononuclear  leukocytes  to arterial  endothelium at  sites  of  atheroma initiation. 
VCAM-1  particularly  binds  those  classes  of  leukocytes  which  are  present  in  the  nascent 
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Fig. 1 Recruitment of mononuclear phagocytes to the nascent atherosclerotic plaque and functions of these 
cells in the mature atheroma (Libby P, 2002).
atheroma, namely, monocytes and T lymphocytes. Endothelial cells express it in response to 
cholesterol  feeding  (26),  maybe  because  of  the  inflammation  due  to  modified  lipoprotein 
particles accumulating in the intima in response to hyperlipidaemia, but VCAM-1 can also be 
expressed by other cell types like macrophages, myoblasts, dendritic cell. Pro-inflammatory 
cytokines such as interleukin (IL)-1b or tumour-necrosis factor-a (TNF-a) induce VCAM-1 
expression in endothelial cells by this pathway. Human atherosclerotic lesions contain these 
cytokines.  Thus,  pro-inflammatory  cytokines  may  link  hypercholesterolaemia  to  VCAM-1 
expression.  In  addition  to  VCAM-1,  other  adhesion  molecules  are  involved  in  leukocyte 
adherence, such as  the intracellular adhesion molecules (ICAM-1,2,3), P- and E-selectin (27). 
Platelet  endothelial  cellular  adhesion molecule  1  (PECAM-1) is  another member of the Ig 
family  expressed  by  leukocytes,  platelets  and  endothelial  cells.  PECAM-1  molecules  are 
particularly dense at the junctions between endothelial cells where they mainly participate to 
homophilic  binding  between  adjacent  cells.  Therefore,  they  are  involved  in  endothelium 
integrity and extravasation of cells from the blood compartment into the vessel and underlying 
tissue.
VCAM-1 appeared as an indicator of severity of atherosclerosis since it significantly correlated 
with the extent of peripheral atherosclerosis. However, if adjusted for smoking, the VCAM-1 
lost significance whereas sICAM-l appeared as a better marker of the presence and progression 
of disease.
Mechanisms of Leukocyte Chemoattraction and Activation
After monocytes and T lymphocytes bind the surface of the arterial wall, they migrate into the 
subendothelial space, where they differentiate into macrophages and foam cells. This migration 
is induced by chemoattractants in the intima, such as oxLDL, Lp(a), chemoattractant cytokines 
(chemokines), like monocyte chemoattractant protein (MCP-1), produced by endothelial cells 
and macrophages, interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α), and degraded 
collagens and elastins (28). Among all the mediators, MCP-1 and Lyso-PC (a component of 
oxLDL) are the most important and best characterized chemoattractants in the lesions. 
MCP-1 is already present at an early stage of lesion development and binds to the specific 
receptor CCR-2 at the surface of monocytes. In addition to acting as a chemoattractant, oxLDL 
can  also  inhibit  macrophage  mobility. This  dual  function  of  oxLDL could  explain  why 
macrophages or foam cells fail to return circulation as they are supposed to do. 
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Once resident in the arterial intima, monocytes acquire the morphological characteristics of 
macrophages, undergoing a series of changes that lead ultimately to foam cell formation. The 
monocytes  increase  the  expression  of  several  scavenger  receptors  capable  of  taking  up 
modified  lipoproteins,  i.e.  the  scavenger  receptor  A (SRA),  and  then  internalize  modified 
lipoproteins transforming themselves into foam cells. By secreting a number of growth factors 
and cytokines, they amplify the inflammatory response in the lesion. The macrophage colony-
stimulating factor (M-CSF) has been individuated as a candidate activator of several of the 
steps that stimulate transition of the monocyte to the lipid-laden macrophage. M-CSF augments 
SRA expression, increases production of cytokines and growth factors by these cells, and also 
serves  as  a  survival  and  co-mitogenic  stimulus.  Moreover,  also  granulocyte–macrophage 
colony-stimulating factor (GM-CSF) may promote inflammation in the atheroma. 
Atheroma progression
After formation of the fatty streak, the nascent atheroma typically evolves into a more complex 
lesion, which eventually lead to clinical manifestations. The typical atherosclerotic plaque (also 
called atheroma) contains a lipid or necrotic core covered by a fibrotic layer. This cap is due to 
smooth muscle cells, that, once adhered to the fatty streaks, begin to multiply and lay down an 
abundant extracellular matrix. As the lesion becomes bigger, the arterial lumen narrows until it 
hampers flow and leads to clinical manifestations. According to the classical view, this process 
occurred in an inevitable and progressive fashion gradually during time.  However, clinical 
observations evidenced a discontinus progression. Data that emerged from serial angiographic 
studies suggest that many coronary arterial lesions in humans develop stenoses discontinuously 
(29). 
Two types of plaque are commonly distinguished: stable plaque and instable plaque. Stable 
plaque is usually composed of a small lipid core and covered by a thick fibromuscular layer 
with more smooth muscle and extracellular matrix. Unstable plaque has a large pool of lipid 
core, a thin cap and a large number of inflammatory cells can be present. Stable plaques are the 
major risk for  stenosis or occlusion, since they cause a significant reduction of the vascular 
lumen. Otherwise, vulnerable plaques are fatal, leading to acute coronary syndrome, if they 
rupture, and are associated to thrombosis.
Different mechanisms are supposed to be involved in plaque rupture. Superficial erosion, or the 
formation of microscopic areas of desquamation of endothelial cells that form the monolayer 
covering the intima, frequently occur in both humans and animals with experimentally induced 
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atherosclerosis.  Such  areas  often  trigger  platelet  thrombus  formations.  The  inflammatory 
mediators and oxLDL are responsible of the activation of matrix metalloproteinases (MMPs) 
that degrade the endothelial basement membrane. Meanwhile, when the inflammation prevails 
in  the  intima,  smooth  muscle  cell  production  of  new  collagen  required  for  repair  and 
maintenance of the fibrous cap decreases. The result is endothelial desquamation (30). 
Secondly, disruption of the microvessels that form in atherosclerotic plaques furnishes another 
explanation for sudden plaque progression (31). Atheromas develop microvascular channels as 
a  result  of  neoangiogenesis.  These microvessels could have a  nutritive function promoting 
plaque growth and, like those that form in the diabetic retina, the new blood vessels in the 
plaque may be particularly fragile and prone to micro-haemorrhage. 
The third and most common mechanism of plaque disruption, a fracture of the plaque’s fibrous 
cap, also involves inflammation. Certain pro-inflammatory cytokines, such as IFN-g, can limit 
the synthesis of new collagen by smooth muscle cells. These changes can thin the fibrous cap 
and render it friable and susceptible to rupture. When the plaque ruptures, blood comes into 
contact with the tissue factor in the plaque and coagulates. Fissure of the fibrous cap allows the 
coagulation factors contact with tissue factor, the main pro-thrombotic stimulus found in the 
lesion’s lipid core.
If the thrombus occludes the vessel persistently, an acute myocardial infarction can result. The 
thrombus  may  eventually  resorb  as  a  result  of  endogenous  or  therapeutic  thrombolysis. 
However, a wound healing response triggered by thrombin generated during blood coagulation 
can  stimulate  smooth  muscle  proliferation.  The  increased  migration,  proliferation  and 
extracellular  matrix  synthesis  by smooth  muscle  cells  thickens the  fibrous cap and causes 
further expansion of the intima, often now in an inward direction, yielding constriction of the 
lumen.  Stenotic  lesions  produced by the lumenal  encroachment  of  the fibrose plaque may 
restrict  blood  flow, particularly  under  situations  of  increased  cardiac  demand,  leading  to 
ischaemia, commonly provoking symptoms such as angina pectoris. 
Endothelial Dysfunction: Setting the Stage for Inflammation
Endothelial dysfunction is a broad term that implies diminished production or availability of 
nitric  oxide (NO) and/or  an  imbalance  in  the  relative  contribution  of  endothelium-derived 
relaxing factors, such as prostacyclin, different endothelium-derived hyperpolarizing factors, 
and  C-type  natriuretic  peptide,  and  contracting  factors,  such  as  endothelin-1  (ET-1), 
angiotensin  II  (Ang  II),  tromboxane  A2 and  reactive   oxygen  species  (ROS).  Endothelial 
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dysfunction was initially identified as impaired vasodilation to specific stimuli.  It  was first 
described  in  human  hypertension  in  the  forearm vasculature  in  1990  (32).  Impairment  of 
vasodilation  was  also  described  in  type  I  and  type  II  diabetes,  coronary  artery  disease, 
congestive heart failure and chronic renal failure.
Endothelial dysfunction, as assessed in terms of vasomotor dysfunction, can occur long before 
the  structural  manifestation  of  atherosclerosis  and  thus  can  serve  as  a  predictor  of  future 
cardiovascular events. 
NO,  about  whom  it  will  be  attentively  discussed  further,  is  the  key  endothelium-derived 
relaxing  factor  that  plays  a  pivotal  role  in  the  regulation  of  vascular  tone  and  vasomotor 
function (33). In addition to its vasodilatatory effect, NO also protects against vascula injury, 
inflammation and thrombosis. 
ROS are known to quench NO with formation of peroxynitrite, which is a cytotoxic oxidant, 
and through nitration of proteins, thereby affecting protein function and endothelial function. 
ROS upregulate adhesion (VCAM-1 and ICAM-1) and chemotactic molecules (MCP-1). 
OxLDL causes  endothelial  activation  and  changes  its  biological  characteristic  partially  by 
reducing the intracellular NO concentration. Angiotensin II,  opposes NO action. A recently 
studied  risk  factor,  the  C-reactive  protein  (CRP)  can  promote  endothelial  dysfunction  by 
quenching the production of NO and diminishing its activity.  
The latter  factor  has  raised a  great  interest,  as  an  acute  phase  reactant.  Several  evidences 
suggest that circulating high-sensitivity CRP represents one of strongest independent predictors 
of vascular death, even stronger than LDL cholesterol. CRP has a direct effect on promoting 
atherosclerosis and endothelial cell dysfunction. Human recombinant CRP elicits a multitude 
of effects on endothelial biology favoring a proinflammatory and proatherosclerotic phenotype. 
It  downregulates endothelial  NO synthase, stimulates ET-1 and IL-6, up-regulates adhesion 
molecules and stimulates MCP-1 while  facilitating macrophage LDL uptake. Recently, CRP 
has been shown to facilitate endothelial cell apoptosis and inhibit angiogenesis. In addition to 
the effect on endothelial cells, CRP inhibits bone-marrow derived endothelial progenitor cell 
survival  and  differentiation (34).  Direct  proatherogenic  effects  of  CRP extend  beyond  the 
endothelium to the vascular smooth muscle. It stimulates vascular smooth muscle migration, 
proliferation, neointimal formation ad ROS production. 
The endothelial injury, activation, and dysfunction caused by oxLDL are exerted via lectin-like 
oxidized low-density lipoprotein receptor-1 (LOX-1) activation. LOX-1 was initially identified 
as the principal oxLDL receptor in endothelial cells. Later, it was evidenced its expression in 
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macrophages and smooth muscle cells too. In addition to  ox-LDL binding, LOX-1 can bind 
damaged  or  apoptotic  cells,  activated  platelets,  advanced  glycation  end  products,  and 
pathogenic orgaisms. Under physiological conditions, LOX-1 may play a role in host defense 
or serve to scavenger cellular debris. On the contrary, in pathological state, it can be involved 
in proatherogenic material binding, playing a role in initiating endothelial dysfunction.   
As  previously  said,  oxLDL,  via  upregulation  of  LOX-1,  induces  monocyte  adhesion  to 
endothelium,  increased  production  of  ROS,  apoptosis  of  SMCs  and  modulation  of  MMP 
activity.  Further,  on  plaque  rupture,  activated  platelets  may  interact  with  the  surrounding 
endothelium via LOX-1. This interaction promotes the release of endothelin-1 from endothelial 
cells and stimulates the generation of ROS that inactivate NO.
In response to endothelium injury, the expression of another family of receptors, the protease-
activated receptors (PARs), is increased. PARs are expressed by a variety of cell types in and 
around blood vessels, including endothelial cells, SMCs, and platelets. PAR activation appears 
to promote the inflammatory response within the intimal tissue, enhancing the initiation and 
progression of atherosclerotic plaque. However, the vascular effects of PARs seem to differ 
when compared to the endothelial dysfunction carried on by other inflammatory markers. In 
fact, activation of PAR-1 and PAR-2 in human blood vessels has been demonstrated to produce 
NO, resulting in vasodilation (35).  PAR-2 induces SMC migration,  and platelet  activation, 
permitting their attachment to the atherosclerotic lesion. Thrombin too can induce the PAR-
mediated platelet activation, and recent studies confirm thrombin-PAR-1 connection. PAR-1 
has emerged to be the primary receptor that mediates the prothrombotic actions of thrombins. 
Another class of enzymes, the matrix metalloproteinases (MMPs), plays an important role in 
vascular remodelling, which permits changes in size and composition of adult blood vessels, 
allowing adaption and repair. However, excessive MMP expression may cause inappropriate 
vascular remodelling, resulting in atherosclerosis. Among MMPs, MMP-9 plays a pivotal role 
in  cardiovascular  disease,  being  its  variation  related  to  the  presence  and  severity  of 
atherosclerosis.  For  instance,  MMP-9  levels  are  increased  in  type  2  diabetic  patients,  and 
patients with acute myocardial infarction and unstable angina. Finally, MMP-9 has also been 
demonstrated  to  promote  the  mobilization  of  stem cells  from bone  marrow, the  so-called 
endothelial progenitor cells, which appear to home preferentially to sites of vascular or tissue 
injury, contributing significantly to both reendothelialization and neovascularization (36).
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Chapter 3
Diabetes as a Vascular Disease
Diabetes  mellitus  is  a  multifactorial  disease,  characterized  by  high  blood  glucose  levels, 
associated  with  a  number  of  microvascular  (retinopathy, neuropathy and nephropathy)  and 
macrovascular  (ischaemic  heart  disease,  cerebrovascular  disease  and  peripheral  vascular 
diseases)  complications  (37).  Type 1  diabetes  is  characterized  by  a  near-total  reliance  on 
exogenous insulin for survival, caused by an  autoimmune-mediated destruction of pancreatic 
islet cell. Type 2 diabetes is more prelevant, and characterized by relative insulin deficiency 
and or insulin resistance. Some type 2 DM patients require exogenous insulin, but many can 
achieve  glucose  control  with  diet  alone  or  the  addition  of  oral  hypoglycemic  agent.  This 
disease is becoming more and more common, because of aging population and the increasing 
prevalence of obesity and sedentary lifestyle (38). 
Recent attention has also focused on the prediabetic spectrum of impaired glucose metabolism, 
with a growing population of patients identified with insulin resistance (IR), impaired glucose 
tolerance,  and  obesity.  Hypertriglyceridemia,  IR,  decreased  high-density  lipoprotein 
cholesterol,  hypertension,  and  central  obesity  are  clustered  factors  known  as  “metabolic 
syndrome,” which portends increased cardiovascular risk (39). 
Cardiovascular disease (CVD) is the major cause of morbidity and mortality in people with 
diabetes, and coronary heart disease is the most common cause of death among people with 
type  2  diabetes.  People  with  diabetes  are  two to  four  times  more  likely  to  develop  CVD 
compared with people without this condition. Diabetes is the leading cause of end-stage renal 
failure,  visual  impairment,  and  blindness  in  many  populations  in  both  developed  and 
developing countries.  Lower extremity amputations are at  least  10 times more common in 
people with diabetes than in non-diabetic individuals in developed countries and more than half 
of all non-traumatic lower limb amputations are due to diabetes. 
Diabetic  macrovasculopathy  is  associated  with  structural  and  functional  changes  in  large 
arteries: structural changes result mainly from glycation of wall components and functional 
changes originate in endothelial  dysfunction. Moreover, metabolic [advanced glycation end 
production  (AGE),  cytokines],  humoral  (renin–angiotensin  system,  endothelin,  sympathetic 
nervous system) and haemodynamic (arterial hypertension and mechanical factors contribute to 
the characteristic dysfunction in diabetic vasculopathy.
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Endothelial Dysfunction and Diabetes
Endothelial dysfunction is a common finding in type 2 diabetic patients. Several independent 
factors, e.g. insulin resistance, hyperglycemia, hypertension, dyslipidaemia, abdominal obesity 
and low-grade inflammation, have all been associated with this condition in subjects with type 
2 diabetes (40). 
I nsulin resistance  . A number of different altered metabolic states as exemplified by glucose, 
lipid and cytokine metabolism can lead to peripheral insulin resistance. The ensuing metabolic 
dysregulation  that  occurs  as  a  consequence  of  insulin  resistance  further  exacerbates  its 
progression. Obesity and insulin resistance, independently of other risk factors, are associated 
with endothelial dysfunction. In the insulin resistant state the normal suppression of free fatty 
acids (FFA) release from adipose tissue is impaired contributing to diabetic dyslipidaemia i.e. 
VLDL-hypertriglyceridemia,  low HDL-cholesterol  concentrations  and  elevation of  FFA. In 
insulin resistance and type 2 diabetes a state of pro-atherogenesis and low-grade-inflammation 
occurs (e.g. reflected by plasminogen activator inhibitor-1 (PAI-1), hematocrit, family history 
of type 2 diabetes, glucagon like peptide-1 (GLP-1),  increased TNF-alpha, IL-6, and CRP-
levels), all of which have been associated with endothelial dysfunction.
At molecular level, insulin has also a profound stimulatory effect on eNOS gene expression 
and on the activity of this important enzyme (41). These effects of insulin on eNOS expression 
and activity and, consequently, on NO production are mediated via thePI3-kinase-dependent 
signalling pathway. Under normal circumstances, NO, in addition to its vasodilatory function, 
counteracts  the  influence  of  vascular  endothelial  growth  factor  (VEGF)  on  expression  of 
adhesion molecules on the surface of the ECs. In the state of metabolic insulin resistance, 
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Fig. 2 Mechanisms for the contribution of insulin resistance to atherosclerosis. In vitro model of metabolic 
insulin resistance with compensatory hyperinsulinemia in vascular endothelium. Kim et al. Circulation 2006; 
113: 1888
insulin  action  via  the  PI  3-kinase-dependent  pathway is  diminished  (42).  As  a  result,  the 
influence of insulin on eNOS activity and NO production declines significantly. Inadequate NO 
production fails to prevent VEGF-induced increases in the expression of adhesion molecules 
and interactions of monocytes with ECs (43). The latter can have strong proatherosclerotic 
consequences. 
H  yperglycaemia  . Hyperglycaemia is a hallmark of diabetes and of both impaired fasting and 
postprandial glucose tolerance (44). High glucose concentration exerts its detrimental action on 
the  cardiovascular  system  in   multiple  ways.  Through  increased  formation  of  advance 
glycosylation  end  products  (AGE),  it  generates  reactive  oxygen  species  (ROS),  activates 
proinflammatory transcription and alters the structural and biochemical function of numerous 
proteins. Through protein kinase C (PKC) activation, it can lead to a variety of phosphorylation 
events that alter intracellular signalling. Hyperglycaemia and AGE and PKC have been shown 
to  activate  mitogen-activating  protein  kinase  (MAP)  that  can  lead  to  proliferative  events. 
Excess of glucose flux into the cells can enter the glucosamine pathway where it  leads to 
abnormal glycosylation of critical proteins such as the transcription factor SP-1, resulting in 
abnormal gene expression. 
Hyperglycaemia rapidly activates a series of stress pathways in the ECs, leading to disruption 
of  the  antiatherogenic  properties  of  healthy  endothelium.  ECs  exposed  to  high  glucose 
concentration (25 mM) acutely generate increased  ROS and ultimately undergo apoptotic cell 
death (44). This injurious effect of hyperglycaemia is likely mediated via induction of PKC, 
accumulation of AGE, shunting glucose molecule into the polyol and glucosamine pathways 
and overwhelming mitochondrial oxidative capacity, leading to generation of mitochondrial 
ROS and poly(ADP-ribose) polymerase activation. Hyperglycaemia acutely activates and later 
inhibits the PI 3-kinase/Akt pathway that regulates endothelial NO synthase (eNOS) and cell 
survival and proliferation (45). AGE-receptor activation and PKC activation induce expression 
of adhesion molecules, cytokines, CD 36 and PAI-1 (46). 
Moreover,  hyperglycaemia  has  effects  on  ECs,  by  induction  of  matrix  protein  and 
metalloproteinase expression in ECs, and interfering with re-endothelialization by disrupting 
the proliferation and migration of ECs. By this series of events, hyperglycaemia promotes a 
vasoconstrictive, proinflammatory and prothrombotic vascular response to injury, which may 
be compounded by compensatory hyperinsulinaemia of insulin resistance. 
I nflammation  . The association of the inflammatory state with obesity and insulin resistance 
was described in 1993 by  Hotamisligil et al. (47). In this study, adipocyte expression of the 
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pro-inflammatory cytokine tumour necrosis factor alpha (TNFα) was observed to be markedly 
increased  in  obese  mice,  and  neutralisation  of  TNFα  led  to  an  improvement  in  insulin 
resistance.  The enhancement of  inflammation by a  diminished endothelial  insulin  response 
could in itself be one possible explanation, since insulin exerts anti-inflammatory effects at the 
cellular and molecular level both in vitro and in vivo. A low-dose infusion of insulin has been 
shown  to  suppress  NADPH  oxidase  expression  and  ICAM-1  and  MCP-1  concentrations. 
Conversely, a longer-term insulin infusion (over four hours) in normal subjects was associated 
with  induction of  endothelial  dysfunction.  Type 2  diabetes  may in  part  be  precipitated  or 
accelerated by an acute phase reaction as part of the innate immune response, in which large 
amounts of cytokines are released from adipose tissue. These cytokines (TNF-alpha, IL-6, PAI-
1)  and  adipokines  (adiponectin  and  leptin)  have  been  suggested  to  be  associated  with 
inflammation and insulin resistance.  
Finally,  the  metabolic  syndrome  and  type  2  diabetes  are  characterised  by  several 
haemodynamic and metabolic abnormalities. In the increased CVD risk found in persons with 
diabetes and hypertension, endothelial dysfunction would play an important role. Alterations in 
the vascular endothelium linked to diabetes include elevated expression and plasma levels of 
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Fig. 3 Influence of diabetes and insulin resistance on progression of atherosclerosis. (AGE, advance 
glycosylation end products; CREB, cAMP response element–binding protein; eNOS, endothelial NO synthase; 
MCP-1, monocyte chemoattractant protein-1; NO, nitric oxide; PAI-1, plasminogen activator inhibitor-1; PKC, 
protein kinase C; ROC, reactive oxygen species; a-SMA, SM-actin; SREBP-1, sterol regulatory element–
binding protein-1; VSMC, vascular smooth muscle cells.
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vasoconstrictors,  such as angiotensin II  and endothelin-1,  increased expression of adhesion 
molecules  and  associated  enhanced  adhesion  of  platelets  and  monocytes  to  vascular 
endothelium, plus impairment of NO release and reduced NO responsiveness. In conclusion, 
endothelial  dysfunction  seems  to  be  the  trigger  in  atherogenesis  and  diabetes-associated 
vascular disease and explains, at least in part,  the enhanced progression of CVD in type 2 
diabetes. 
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Chapter 4
E  ndothelial Progenitor Cells  
In  1997 it  was  first  observed  that  cells  present  in  the  adult  circulation  of  human healthy 
volunteers acquired an endothelial cell-like phenotype in vitro and incorporate into capillaries 
in  vivo  (48).  These  bone-marrow  derived  cells  were  defined  endothelial  progenitor  cells 
(EPCs)
Until then, only resident endothelial cells were thought to participate to vessel formation and 
remodelling,  processes  referred  to  as  vasculogenesis,  angiogenesis  and  atherogenesis. 
Vasculogenesis denotes  de  novo  blood  vessel  formation  during  embryogenesis,  in  which 
angiogenic  progenitor  cells  migrate  to  vascularization  sites,  differentiating into  endothelial 
cells.  The formation of  new capillary-like  vessels from an existing blood vessel is  termed 
angiogenesis,  while  arteriogenesis  refers  to  existing  artery  remodelling  (49).  Angiogenesis 
leads  to  the  creation  of  small,  high-resistance  capillaries  and  arteriogenesis  to  large 
interconnetting arterioles. Both angiogenesis and arteriogenesis appear to be necessary for the 
resolution of tissue ischemia. Clinical  angiogenesis trials  using angiogenic factors,  such as 
vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) failed to 
reverse ischemic condition. The formation of small peri-ischemic capillaries is insufficient. 
Thereafter,  findings  on  EPCs  have  drastically  changed  the  understanding  of  new  vessel 
formation,  since  endothelial  progenitor  cells  showed having  a potential  that  relies  to  their 
ability to mature into endothelial cells: re-endothelization and neovascularization. It is now 
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Fig. 4  Postnatal neovascularization in physiological or pathological condition via angiogenesis and  
vasculogenesis (Iwaguro H et al. 2005).
blood vesselbasal membrane
recognised  that  a  portion  of  normal  endothelium derives  from  circulating  EPCs,  that  are 
incorporated  in  situ  with  subsequent  differentiation (50).  Moreover, studies  evidenced  the 
EPCs should reside in vessel walls (51). 
Vasculogenesis is in response to endothelial injury, due to wound healing (52), limb ischemia 
(48), burns, coronary bypass and myocardial infarction (53), or in response to physiological 
processes, as for endometrium organogenesis (54).
In vivo studies, in which donor bone-marrow derived EPCs had been marked before injection, 
showed that EPC contribution to new vessel formation vary from 5 to 25%  in response to 
“exogenous” stimula,  i.e. granulocyte-colony stimulating factor (G-CSF) pretreatment (55) or 
angiogenic growth factor pretreatment (56). Moreover, in tumor vasculogenesis, this rate can 
raise to 35-45% (57). 
EPCs Isolation
EPCs can be isolated from peripheral blood (48), cord blood and bone marrow. Recently, EPCs 
have been isolated in different tissues,  such as the endothelium itself (51),  skeletal muscle 
tissue (58), cardiac tissue (59), adipose tissue (60) and finally, nervous tissue (61).
Bone Marrow Peripheral blood Tissue-resident cells
hematopoietic stem cells CD133+/KDR* cells Endothelial tissue
SP-cells Myeloid intermediates Adipose Tissue (HSC, MSC)
Mesenchymal stem cells Cardiac progenitor cells
Neuroprogenitor cells
Asahara and coworkers first isolated EPCs from human peripheral blood by magnetic-bead 
immunoselection of mononuclear cells (MNCs) expressing the hematopoietic antigen CD34 
(MNCsCD34+)  (48). They first  described that  these bone-marrow derived hematopoietic stem 
cells (HSCs) can give rise to ECs and contribute to endothelial recovery. Isolated cells were 
cultured for 7-10 days under endothelial differentiating conditions and gave origin to adherent, 
spindle-shaped cells: the so-called AT cells (spindle-shaped adherent and attaching cells). Once 
injected in mouse ischemic limb, these cells contributed to neovascularization.
Because CD34 is not exclusively expressed in hematopoietic stem cells but, at lower level, in 
ECs too, EPC linage was characterized via the expression of another hematopoietic marker, a 
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Tab.4. Various cell types which have been differentiated into endothelial cells.
120 kDa glycosilated polypeptide,  with  5  transmembrane-domains,  CD133 (initially called 
AC133) (62). CD133 expression defines a very early population of progenitor cells, immature 
HSCs, in which the two sub-fractions of adult bone-marrow stem cells (the hematopoietic and 
the mesenchymal subset) seem to be represented. 
Because of MNC population heterogeneity, several other studies have tried to better define the 
EPC characteristics. EPCs should express CD34, CD133 and VEGF receptor-2 (VEGFR-2), 
also known as flk-1 or KDR.
Recent studies have shown that also cells expressing CD14 antigen (monocytes/macrophages) 
(63), can effectively participate to neovasculogenesis, either CD34 negative or CD133 negative 
(64).  Despite  the  different  subpopulation  characteristics,  also  these  cells  show  analogue 
vasculogenic abilities (65), suggesting that EPCs represent a heterogeneous group at various 
differentiation stages.
EPC origin and differentiation
Evidences suggest that, in embryonic development, hematopoietic stem cells and EPCs share 
some markers and possibly derive from a common precursor: the hemangioblast (66). 
The contribution of HSCs to neovascularization improvement has been documented by using 
bone  marrow transplantation  with  tagged  cells  to  replenish  HSCs  after  irradiation.  These 
tagged  cells  home  to  sites  of  ischemia  and  contribute  to  vessel  formation.  Therefore, 
hematopoietic stem cells were suggested as candidates of EPC precursor cell population. The 
first studies supporting this concept were performed with isolated cells expressing the classic 
HSC  marker  protein  CD34  or  the  more  immature  one  CD133.  Both  cell  population 
differentiated in ECs in vitro under appropriate endothelial differentiating conditions. 
HSCs  and  EPCs  share  some  surface  proteins,  such  as  CD34,  CD133,  VEGFR-2,  Tie-2 
(angiopoietin 1 receptor), CD117 and Sca-1 (stem cell antigen-1). Once EPCs are mobilized 
from bone-marrow, they begin to loose stem cell markers (initially CD133 and later CD34) and 
to  express  endothelial-specific  markers,  such  as  von  Willebrand  factor  (vWF),  vascular 
endothelial-cadherin (VE-cadherin) and E-selectin (67). Gulati and coworkers suggested the 
classification of cultured EPCs in two types: early EPCs, which at 7 day culture present the 
monocyte marker CD34, and late outgrowth endothelial cells (OECs) (68). These cells appear 
from the third week of culture on and are  developed exclusively from the CD14- fraction. 
Human OECs, but not EPCs, expressed the key regulatory proteins endothelial nitric oxide 
synthase (eNOS) and caveolin-1. The CD14- population express endothelial markers and have 
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great expansion capacity. Successive studies confirmed the expression of monocyte  markers 
(CD14) or macrophage ones (CD11 e CD45) in 4-7 day cultured EPCs (63), that is associated 
to a lower proliferation capacity than HSCs or cord-blood derived EPCs.
Finally, these monocyte derived cells present a  CD133+/-, CD34+, VEGFR-2+, CD14+, VE-
cadherin-, and eNOS- phenotype. From the CD14- subpopulation it is possible to obtain late 
EPCs with a more endothelial-like phenotype (CD133-, CD34+/-, VEGFR-2+, CD14-, VE-
cadherin+,  eNOS+, and vWF+). 
However,  the  heterogeneity  of  EPC  population  make  it  difficult  to  have  a  precise 
characterization of effective EPCs. 
A comparative study evidenced that, just after isolation, MNCs in toto, both CD14- and CD14-, 
are ineffective for neovascularization. Nevertheless, after 7 day culture in the same endothelial-
differentiating  conditions,  both  cell  subpopulations  had  analogue  ability  to  incorporate  in 
newly blood vessels and improved neovascularization (65). 
EPC characterization
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Fig. 5 Putative cascade and expressional profiles of human bone marrow-derived endothelial progenitor cell 
differentiation. (+: positive, –: negative).
As we previously said, it does not exist a way to  unequivocally define EPCs, excepting the 
capacity  of  a  non-EC to adapt  an endothelial  phenotype,  and the  stemness  characteristics. 
However, a series of parameters can be adopted in order to better characterize EPCs. 
a. Morphological characteristics
Whichever the EPC subtype is, the cell has a spindle shape and is adherent to the substratum. 
Asahara first defined them as  spindle-shaped adherent and attaching cells (AT cells). 
Others defined hematopoietic cell progenitors by their ability to form colonies or small clusters 
of cells. Colonies are defined as a cell mass composed of a central cord of round cells with 
elongated spindle-shaped cells sprouting at the periphery of the colony, namely colony-forming 
unit  endothelial  cells  (CFU-ECs).  The cluster  of round cells  sits  on top of spindle shaped 
adherent cells that emigrate from the base of the cell cluster. Over time, the cluster of cells 
disappears, leaving the adherent spindle-shaped cells that display features of endothelial cells. 
Some authors consider only the CFU cells the real endothelial progenitor (69).  After a long-
term culture (3-4 weeks), colonies disappear and late progenitor cells, OECs, are observed. 
These  cells   are  disposed  in  a  monolayer,  with  a  typical  cobblestone  aspect  of  mature 
endothelial  cells  (68).   Moreover, thanks to electronic  microscopy, it  has  been possible to 
observe  cylindric  structures,  containing  microtubules,  which  are  characteristic  of  vascular 
endothelium (70).
b. Antigenic characterization
One of the most important endothelial markers is the VEGF receptor-2, that is the only marker 
that is expressed in the hemangioblast, and keeps to be expressed during cell differentiation 
(67).  VEGF, an endothelial-specific  mitogen and survival  factor, is  one of the most  potent 
angiogenic  factors.  It  is  crucial  for  both  angiogenesis  and  vasculogenesis,  promoting,  for 
instance, EPC recruitment (54) and is used in all endothelial differentiating cocktails. VEGF 
contribute to cell mobilization also via VEGF receptor 1 (VEGFR1 of flt-1). 
Moreover, other markers whose expression is studied for EPC characterization are vWF, some 
endothelial adesion molecules, such as platelet endothelial cell adhesion molecule (PECAM-1 
o CD31), VE-cadherin, and E-selectin. In addition, being the endothelial NOS constitutively 
expressed by vascular endothelial cells,  its expression is eventually considered a marker of 
endothelial differentiation.
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c. Functional Characteristics
As previously said, some authors think that the colony forming ability can be considered as a 
typical characteristic of hematopoietic cells. According to Ingram and coworkers, by plating 
hematopoietic cells in special double-layer agar cultures with multiple recombinant cytokines, 
it also possible the identification of two types of clonal hematopoietic progenitors: the highly 
proliferative (high-proliferative potential–colony-forming cells or HPP-CFCs)  and the more 
differentiated low-proliferative potential–colony-forming cell (LPP-CFC), HPP-CFC colonies 
are visible in the culture dishes without need for magnification. HPP-CFC clones could be 
replated  in  CFC  assays  with  emergence  of  secondary  HPP-CFCs,  as  well  as  committed 
erythroid and myeloid and multipotent progenitors. On the contrary, LPP-ECFCs form smaller 
colonies  but  do  not  form  secondary  LPP-ECFC  colonies  upon  replating;  this  EPC  stage 
represents the most proliferative population of EPCs that can be isolated from healthy adult 
peripheral blood. They do give rise to endothelial cell clusters and these endothelial cluster-
forming cells give rise only to mature non-dividing ECs.
Another  important  functional  characteristic  is  the  capacity  to  form cord-  and  tubular-like 
structures  in  three-dimensional  gels,  like  Matrigel  (71),  as  mature  endothelial  cells  do. 
Additionally, migratory capacity of EPCs is tested. It can be assessed by their ability to cross 
the membrane  of  a modified  Boyden chamber, in presence of chemotactic stimuli. Migrated 
cells  are  collected  in  the  transwell  support,  then  are  counted  by  light  microscopy. NO 
production is also considered an index of endothelial functionality. 
A commonly used  characterization of endothelial differentiation is based on EPC functions of 
uptaking  acetylated  low density  lipoproteins  (AcLDL)  and binding  lectin,  Ulex  europaeus 
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Fig. 6. Endopoiesis: the process of endothelial cell development suggested by Ingram DA et al. 2005.
agglutinin-1 (UEA-1). While ac-LDL uptake is dependent on scavenger receptors common to 
monocytes, UEA-1 binding is considered more specific for endothelial cells.
Mobilization and homing of EPCs
The mobilization of EPCs from the bone marrow is a complex process, regulated by a variety 
of enzymes, growth factors and surface receptors (72). An initial step in this recruitment is 
represented  by the  activation  of  matrix  metalloproteinase-9  (MMP-9),  which promotes  the 
transformation of membrane bound Kit ligand to a soluble Kit ligand (sKitL). This activation is 
followed by detachment of early cKit-positive progenitor cells from the bone marrow stromal 
niche and their subsequent movement to the vascular zone of the bone marrow. Growth factors 
such as VEGF, PIGF, Ang-1 and stromal-derived factor-1 (SDF-1) induce the mobilization and 
the expansion of EPC and HSC populations in the bone marrow. VEGF, which binds to its 
receptor VEGFR-2 (termed also Flk-1 or KDR), mediates the further maturation of the axis 
“bone marrow angioblast-early EPC-late EPC”.  VEGF may also activate MMP-9, and that 
would confirm its key role in the process of recruitment and release of EPCs. In addition, 
eNOS  expressed  by  bone  marrow  stromal  cells  may  also  influence  the  recruitment  of 
angiogenic progenitor cells and thus play an essential role for their mobilization, since recent 
data  have  demonstrated  impaired  mobilization  of  EPCs  in  eNOS-deficient  mice  (73). 
Furthermore, this eNOS deficiency was related to a reduced activity of MMP-9.
Physiologically, ischemia is believed to be the predominant signal to induce mobilization of 
EPCs from the bone marrow (74). Thereby, ischemia is believed to upregulate VEGF or SDF-
1, which in turn are released to the circulation and induce mobilization of progenitor cells from 
the  bone  marrow  via  a  MMP-9-dependent  mechanism.  Additional  factors  inducing 
mobilization  of  progenitor cells  from the  bone  marrow  have  been  initially  discovered  in 
hematology to harvest hematopoietic stem cells from the peripheral blood for bone marrow 
transplantation.  For  instance,  granulocyte-colony stimulating  factor  (G-CSF),  a  cytokine, 
which is typically used for mobilization of CD34+ cells in patients, also increased the levels of 
circulating endothelial progenitor cells. A related cytokine, the granulocyte monocyte-colony 
stimulating factor (GM-CSF), augments EPC levels. Moreover, erythropoietin (EPO), which 
stimulates proliferation and maturation of erythroid precursors, also increased peripheral blood 
endothelial progenitor cells in mice and in men. The correlation between EPO serum levels and 
the number of CD34+ or CD133+ hematopoietic stem cells in the bone marrow in patients with 
ischemic coronary artery disease further supports an important role of endogenous EPO levels 
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as a physiologic determinant of EPC mobilization. At present, it  is  not  clear which of the 
mobilizing factors most potently elevates the levels of EPCs. Whereas a similar increase in 
white  blood  cell  counts  was  achieved  by  G-CSF  application,  the  number  of  endothelial 
colonies (CFU-EC) was significantly lower in G-CSF- compared to VEGF- or SDF-1-treated 
mice.  In  addition,  the extent  of  increasing  neutrophil  and  lymphocyte  levels,  which may 
provoke  proinflammatory  responses,  has  to  be  considered for  a  potential  therapeutic 
application.
It has also been observed a pharmacological modulation of systemic EPC levels. Statins were 
shown to increase the number and the functional activity of EPCs in vitro, in mice, and in 
patients with stable coronary artery disease. The increase in EPC numbers was associated with 
increased  bone marrow-derived  cells  after  balloon  injury  and  accelerated  endothelial 
regeneration.  Recent studies  demonstrated that  estrogen  increased  the levels  of  circulating 
EPCs. 
Once  mobilized,  EPCs were released from the vascular zone of  the bone marrow into the 
circulation. To date, no clear definition exists as to when a circulating EPC turns into a mature, 
fully differentiated endothelial  cell  in  vivo.  An initiation of this differentiation may by the 
migration of EPCs from the bone marrow into the peripheral circulation and after adhesion and 
insertion into the monolayer of surrounding mature endothelial cells this differentiation process 
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Fig. 7. Mechanism of EPC homing and differentiation. Factors that are proposed to regulate the distinct 
steps are indicated (Urbich C. et al. 2004)
may be  completed.  However, the  exact  differentiation cascade  of  EPCs  in  vivo  is  hardly 
comprehensible. 
Adhesion molecules of the selectin and integrin family are also essential for EPC arrest to 
endothelial cells (75). EPCs have been found to exhibit surface expression of the P-selectin 
glycoprotein ligand-1 (PSGL-1) and to be recruited on activated endothelial cells in a P- and E-
selectin-dependent  manner.  Moreover,  chemokines  have  been  shown  to  trigger  integrin 
activation  to  mediate  arrest  of  rolling  leukocytes.  Isolated  human  EPCs  demonstrated 
significantly  increased and constitutive adhesion on  the  β2-integrin  ligands fibrinogen and 
ICAM-1 under physiological flow conditions in vitro. Functionally active β2-integrins (LFA-1, 
Mac-1)  further  mediated  arrest  of  EPCs  to  mature  endothelial  cells  and  their  subsequent 
emigration into tissues, implying the importance of this integrin subclass not only after arterial 
injury but  also during angiogenesis in ischemic regions,  where sprouting of  newly formed 
capillary  structures  is  required.  The  association  of  β2-integrins  with  the  homing  of 
hematopoietic progenitor cells (including also EPC populations) during neovascularization was 
demonstrated in a mouse model of hind limb ischemia (76). In addition to β2-integrins, β1-
integrins have also been involved in the homing of bone marrow-derived progenitor cells to the 
remodeling vasculature. The α4β1 integrin (also known as very late antigen-4, VLA-4) plays 
an important role in EPC homing. Blockade of VLA-4 significantly reduces the incorporation 
of CD34+ cells to areas of active tumor vascularization, and, recent data revealed a critical 
involvement of VLA-4 in the homing of human EPCs to ischemic tissue (77). Vascular cell 
adhesion molecule (VCAM) but also fibronectin are well known ligands for VLA-4. While 
VCAM is primarily up regulated in ischemic tissue, interaction of VLA-4 with fibronectin 
occurs mainly when denuded vascular ECM is exposed to the blood flow, e.g. after endothelial 
injury.  
It is conceivable that coating of biomaterials by EPC attracting compounds may be helpful for 
tissue engineering. Similar in-vivo effects on accelerated reendothelialization were observed 
after short-term treatment with statins, when a significant up-regulation of α5, β1 and αvβ5 
integrins on the EPC surface was also noted. Local delivery of VEGF-A within a region of 
endothelial denudation, e.g. after stent implantation, may be helpful to selectively attract EPCs 
and to achieve stent endothelialization, but has to be scrutinized with caution in the context of 
advanced atherosclerosis due to the risk of plaque destabilization. Finally, coating strategies 
with  antibodies  against  progenitor  cell  antigens  (e.g.  CD34)  were  reported  to  effectively 
accelerate endothelialization by capturing circulating EPCs after stent placement or vascular 
graft implantation.
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Conditions and factors influencing the number and the recruitment of EPCs
Physiological variations in the number of EPCs have been recently described. For example, 
estrogens and physical training enhance the number of circulating EPCs. Several studies have 
further described the influence of various pathological conditions and some drugs and growth 
factors on the number of EPCs in vivo (see Table 5). In this context, the number of circulating 
EPCs and their migratory activity have been reported to be reduced in patients with risk factors 
for ischemic cardiovascular disease, such as genetic predisposition or smoking. 
The  functional  capacity  of  EPCs  to  form  CFUs  is  also  negatively  correlated  with  the 
Framingham risk score. Furthermore, EPCs from patients with diabetes mellitus type 2 are 
characterized by a decreased proliferative capacity, impaired homing and reduced ability for 
formation of capillary  tubes  in vitro (78). A similar EPC-dysfunction was found in patients 
with  type  1  diabetes.  On  the  other  hand,  acute  myocardial  infarction  is  associated  with 
mobilization and a rapid increase of circulating EPCs. Similarly to acute cardiovascular events, 
vascular trauma such as coronary bypass grafting or burn injury induces a rapid but transient 
mobilization  of  VEGFR2+/AC133+  EPCs.  Additionally, a  biphasic  variation  in  the  EPC-
number has been oberved in patients with chronic heart failure, namely elevation in the early 
and reduction in the advanced phases (79). 
Drug intake can also influence the number and the migratory activity of EPCs. For example, 
treatment with HMG-CoA reductase inhibitors increase the number of circulating EPCs, which 
may  contribute  to  endothelial  repair  after  balloon  catheter  injury  or  to  angiogenesis,  by 
activation of the PI3-kinase/Akt pathway in EPCs. The number of EPCs can also be increased 
after application of several chemokines and cytokines, such as VEGF, placental growth factor, 
erythropoietin or G-CSF. Some chemokines regulating the recruitment of mononuclear cells 
during the development of atherosclerotic vascular lesions may influence also the recruitment 
of EPCs. For example, early EPCs can be mobilized by stromal cell-derived factor-1 (SDF-1), 
that has been shown further to protect EPCs from apoptosis. 
EPCs and atherosclerosis
If EPCs contribute to an enhanced endothelial cell repair after focal endothelial cell damage, 
EPCs may have a pivotal role in maintaining the integrity of the endothelium in conditions of a 
dissiminating  endothelial  cell  damage as  seen for  example  in  endothelial  dysfunction,  the 
earliest manifestation of atherosclerotic disease.
29
In a key publication, Rauscher and colleagues demonstrated that the systemic transfusion of 
stem  and  progenitor  cells  derived  from  young  nonatherosclerotic  ApoE-/-  mice  prevents 
atherosclerotic lesion progression in ApoE-/- recipients despite persistent hypercholesterolemia 
(80).  Treatment  with  bone  marrow  stem  cells  from  aged  ApoE-/-  mice  with  manifest 
atherosclerosis  did  not  effectively  prevent  atherosclerotic  lesion  progression.  Apparently, 
endothelial cell repair capacity depends on the age of stem cells, underlining the important 
influence of cardiovascular risk factors on the bone marrow. First evidence that EPCs have a 
vasculoprotective action in patients with atherosclerotic disease comes from the  Endothelial  
Progenitor Cells in Coronary Artery Disease (EPCAD) study. The number of CD34+/KDR+ 
EPCs was measured in 519 patients with angiographically documented CAD and correlated 
with cardiovascular outcomes (81). Primary endpoints included cardiovascular mortality, the 
occurrence  of  a  first  major  cardiovascular  event  (myocardial  infarction,  hospitalization, 
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Table 5. Conditions, drugs and cytokines that may affect number and function of human EPCs.
revascularization, and cardiovascular death), revascularization,  hospitalization, and all-cause 
mortality  after  12  months.  After  adjustment  for  vascular  risk  factors,  drug  therapy, and 
concomitant disease, increased EPC levels were independently associated with a lower risk for 
cardiovascular  events.  In  a  subgroup  of  patients  the  number  of  colony  forming  units 
endothelial cells (CFU-EC), considered as a marker of the clonogenic potential of formerly 
circulating EPCs, was determined. It resulted that the number of circulating cells the functional 
capacity is closely correlated with cardiovascular event rates. In a study by Hu et al. neointimal 
lesions  in  allografts  contained  endothelial  cells  derived  from  circulating  progenitor  cells, 
suggesting a role of EPCs in plaque angiogenesis (82). 
EPCs and Diabetes
Numerous studies have demonstrated an effect of hyperglycaemia on EPC biology. Culturing 
EPCs derived from healthy subjects under high glucose conditions impaires EPC number and 
function (83). Glucose effect on EPCs is because of a dose and time-dependent activation of 
the p38 mitogen-activated protein (MAP) kinase. If cultured in high glucose conditions, these 
cells  present  impaired  function  and  decreased  nitric  oxide  and  matrix  metalloproteinase 
(MMP)-9  production  (84).  BM-MNCs  derived  from  streptozotocin-induced  diabetic  mice 
differentiate less efficiently into EPCs. Albeit, they have a lower expression  of eNOS and 
VEGF. Injecting non-diabetic EPCs in diabetic and non-diabetic recipients, no real difference 
is observed in cell recruitment, suggesting that short term exposure barely affects EPC function 
in vivo. The impaired neovascularization associated with diabetes may be explained by the 
inability of diabetic EPCs to respond to SDF-1, an important factor in EPC homing.  
Several studies in type 1 and type 2 diabetes confirmed these preliminar findings. In fact, type 
1 diabetic patients present a reduced number of EPCs and angiogenic capacity. 
A reduced number of EPCs is observed in type 2 diabetes, and a further reduction has been 
seen in those patients affected by peripheral vascular disease. Cells isolated from patients with 
type 2 diabetes demonstrated a  decrease in the adhesion to activated endothelial  cells,  but 
normal adhesion to quiescent endothelial cells, and matrix molecules (78).  
However, in  patients  with diabetic  retinopathy (DR) it  has  been observed a  different EPC 
concentration.  These patients have a  higher number of  EPCs,  and higher plasma levels  of 
VEGF.  This  contrast  has  been  termed  “diabetic  paradox”.  The  enhanced  endothelial 
differentiation of circulating progenitor cells characterizes DR patients, as shown by the high 
CD34+KDR+ proportion and the better EPC efficiency (85).  
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Many therapeutic treatments, such as the use of ACE inhibitors and statins, glycaemic control 
by use of insulin or oral hypoglycamic agents, have been shown to augment EPC number and 
function. Further approaches, such as EPC administration, may represent a novel treatment for 
diabetic vasculopathy.  
Possible Clinical Application of EPCs as Diagnostic and Therapeutic Tools 
The number and the functional characteristics (eg, formation of CFUs, adhesion potential) of 
EPCs may be  successfully  used  as  diagnostic  tool  and/or  surrogate  prognostic  marker  for 
ischemic heart disease.
The possible  clinical  application of  EPCs consist  of  two directions:  neo-vascularization of 
ischemic tissue or endothelialization of denuded endothelium (eg, after balloon angioplasty) 
and of vascular grafts. However, an important limitation for a therapeutic use of autologous 
post-natal EPCs is their low number in the circulation. This low cell number is further reduced 
in patients with risk factors for ischemic coronary heart disease. Approaches to overcome this 
problem include  three  strategies:  (I)  the  ex  vivo  transfection  with  different genes,  (II)  the 
mobilization  of  EPCs  in  vivo,  or  III)  the  local  infusion  of  autologous  bone  marrow  cell 
suspensions without preselection.  Recent  studies demonstrated a significant  increase in the 
number of isolated human EPCs after ex vivo transfection with adenovirus encoding VEGF164 
(86). Gene transfer of the target ischemic tissue with angiogenic chemokines might be another 
effective strategy for therapeutic neo-vascularization. Thus, intramuscular or intramyocardial 
VEGF gene transfer  has  been shown to  mobilize  EPCs in  patients  with  limb ischemia or 
inoperable  coronary  disease.  Similar  results  were  observed  in  a  very  recent  animal  study, 
employing  an  intramuscular  gene  transfer  of  SDF-1  for  mobilization  of  EPCs  (87).  An 
alternative  for  mobilization  of  EPCs  may  be  represented  by  the  HMG-CoA  reductase 
inhibitors.  Several  studies  in  animals  have  shown  a  therapeutic  potential  of  EPCs  for 
improvement  of  the  cardiac  function  after  myocardial  infarction  (88).  Furthermore, 
transplanted  bone  marrow-derived  angioblasts  protect  cardiomyocytes  from  apoptosis  and 
reduce the negative myocardial remodeling after infarction. Consequently, the possibility for 
autologous transplantation of bone marrow-derived mononuclear cells, including also the EPCs 
fraction, could represent a new strategy to obtain therapeutic angiogenesis also in humans. This 
was  explored  for  the  first  time  in  patients  with  chronic  limb  ischemia,  which  showed  a 
significant improvement of the function of the ischemic limbs during a 6-month follow-up 
period after transplantation of mononuclear cells  (89). Further clinical studies evidenced the 
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capacity of autologous bone marrow-derived cells or isolated and ex vivo expanded autologous 
EPCs for partial repair of infarcted myocardium in humans. However, it has not to be excluded 
the possibility of side-effects, such as uncontrolled neovascularization (i.e., tumor-, plaque or 
neointimal-growth).  
In order to overcome this problem, a possible solution could be the local application of EPCs 
close  to  the  ischemic/injured  area  (eg,  intra-coronary  or  intra-myocardial  after  myocardial 
infarction).
Another  intriguing  direction  of  therapeutic  application  for  EPCs  is  the  construction  of 
endothelial-coated vascular grafts in the context of tissue engineering or the use of EPCs for 
reendothelialization  after  balloon  catheter  injury. In  this  case,  a  cell-based  gene  therapy 
strategy  may also be  used.  For  example,  an  interesting study in  rabbits  demonstrated that 
transplantation of autologous EPCs overexpressing eNOS in injured vessels clearly improved 
the function of reconstituted endothelium, leading to prevention of thrombosis and to inhibition 
of the neointimal hyperplasia (90).
One critical point is the definition itself of these endothelial progenitor cells. As mentioned 
above, it does not exist a single phenotype which uniquely characterizes EPCs. Endothelial 
progenitor cells from various sources and with dramatically different expression patterns of 
surface markers have been used successfully to improve neovascularization (91). Moreover, 
early spindle-like cells and late outgrowing EPCs showed comparable in vivo vasculogenic 
capacity. One interpretation could be that different cells share a similar capacity. Alternatively, 
another  explanation  could  be  the  lack  of   appropriate  marker(s)  to  define  the  effective 
population of cells. Given that only a minor percentage of these cells are incorporated into the 
capillaries, a contaminating population common in the different cell sources may account for 
the biological effects in vivo.
The second critical point is how these endothelial progenitor cells enhance neovascularization. 
Various studies showed that  bone marrow–derived cells  incorporate into the newly formed 
capillaries  and  express  endothelial  markers,  suggesting  that  endothelial  progenitor  cells 
enhance  neovascularization  by  physically  contributing  to  the  newly  formed  capillaries. 
However, the absolute number of incorporated endothelial progenitor cells dramatically varies 
between  0%  and  90%  in  the  different  studies.  The  experimental  animal  model  (tumor 
angiogenesis versus limb ischemia), the time point assessed after ischemia, and the use of the 
endothelial marker proteins, which are more or less specific for endothelial cells, may have 
contributed to  these  dramatically  different numbers.  To achieve a  functional  improvement, 
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EPCs need to be ex-vivo cultured to enrich an active subpopulation (which is approximately 
0.5% of total monocytic cells) out of peripheral mononuclear cells. 
Another  possible  mechanism  for  EPC  enhanced  neovascularization  could  be  a  paracrine 
activity of these cells, by the release of proangiogenic factors (74). EPCs may act similar to 
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Table 6. Preclinical and Clinical Studies of Neovascularization Therapies  (Dzau VJ et al, 2005). 
AVDO2 indicates arteriovenous oxygen difference; EF, ejection fraction; PO2, partial pressure of oxigen.
Target Donor Recipient Type and Source of Cells Method of Delivery Therapeutic Effects 
Preclinical
    Myocardial ischemia Swine Autologous CD31+, peripheral blood Transendocardial with 
NOGA mapping
Rentrop score, EF, capillary 
density
    Myocardial ischemia Swine Autologous MNC, bone marrow Transendocardial capillary density, collateral flow, 
myocardial contractility
    Hibernating 
myocardium
Swine Autologous MNC, peripheral blood Transendocardial EF, capillary density, flow
MNC, bone marrow EF, collateral flow
    Myocardial ischemia Rat Autologous MNC, bone marrow Intramyocardial capillary density
    Myocardial infarction Human Nude rat CD34+, peripheral blood Intramyocardial EF, capillary density, fibrosis
MNC, peripheral blood Intravenous EF, capillary density, fibrosis
    Myocardial infarction Human Nude rat CD34+, bone marrow Tail vein injection EF, capillary density, fibrosis,
apoptosis, infarct size
    Myocardial infarction GFP mouse Syngenic 
mouse
Lin–c-kit+, bone marrow Peri-infarct region LVDP, capillary density, infarct,
    Myocardial infarction Mouse Autologous bone marrow mobilization Homing EF, capillary density, 
remodelling,
    Hind limb ischemia Rat Autologous MNC, bone marrow Intramuscular injection 
in
capillary density, blood flow,
Gastrocnemius AVDO2, exercise capacity
    Hind limb ischemia Rabbit Autologous MNC, bone marrow Intramuscular injection 
in thigh
capillary density, blood flow
    Hindlimb ischemia Human Athymic mice MNC, peripheral blood Intracardiac injection capillary density, blood flow
    Hind limb ischemia Human Athymic mice MNC, peripheral blood 
overexpressing VEGF
Tail vein injection autoamputation, capillary density,
blood
    Hind limb ischemia Human Nude rat MNC, peripheral blood Intramuscular injection 
in thigh
capillary density, blood flow
MNC, chord blood
Clinical
    Myocardial infarction Human Autologous CD133+, bone marrow Infarct border EF, collateral flow (SPECT)
    Myocardial infarction Human Autologous MNC, bone marrow Intracoronary balloon 
catheter
infarct size, wall motion,
    Myocardial infarction 
(TOPCARE-AMI trial)
Human Autologous MNC, bone marrow, 
peripheral blood
Intracoronary balloon 
catheter
contractility, myocardial perfusion 
remodeling EF
    Myocardial infarction 
(BOOST trial)
Human Autologous CD34+, bone marrow Intracoronary during 
PCA
    Myocardial infarction Human Autologous CD34+/CD117+/AC133+ Intracoronary with PCA EF, LV wall thickness, ESV
   Myocardial ischemia 
(Unstable angina)
Human Autologous MNC, bone marrow Transendocardial with 
NOGA mapping
anginal episodes, wall thickening, 
wall motion, EF
    Myocardial infarction Human Autologous CD34+ 1: intracoronary, 2: G-
CSF
EF, exercise time, myocardial
(MAGIC trial) mobilization perfusion, angiogenesis
    Hind limb ischemia Human Autologous MNC, bone marrow Intramuscular injection 
in Gastrocnemius
ankle-brachial index, pain-free 
walking, transcutaneous PO2
monocytes/macrophages, which can increase arteriogenesis by providing cytokines and growth 
factors. EPCs cultivated from different sources showed a marked expression of many growth 
factors, such as VEGF, HGF, IGF-1, IL-8 and G-CSF (92), that could increment the angiogenic 
process carried on by the surrounding mature endothelial cells. Moreover, adherent monocytic 
cells, which were cultivated under similar conditions, but did not express endothelial marker 
proteins, also release VEGF, HGF, and G-CSF. In contrast, infusion of macrophages, which are 
known to release growth factors, but were not incorporated into vessel-like structures, induced 
only a slight increase in neovascularization after ischemia, indicating -but not proving- that the 
capacity  of  EPCs to  physically  contribute  to  vessel-like  structures  may contribute  to  their 
potent capacity to improve neovascularization.
Finally, it has to be considered that most of the preclinical studies are performed with healthy 
and young animals.  In order to transfer  the experimental  findings into the clinic,  we must 
consider that the patients usually have an established coronary artery disease, are of advanced 
age,  and have various risk factors  such as diabetes,  hypercholesterolemia,  or hypertension. 
These circumstances may limit the effect of cell or gene therapy. Evidences suggest that the 
fundamental  mechanism  by  which  therapeutic  neovascularization  augments  collateral 
development is to provide cytokine supplements to individuals who, because of advanced age, 
diabetes,  hypercholesterolemia,  or  other  as  yet  undefined  circumstances,  are  unable  to 
appropriately  upregulate  cytokine  expression  in  response  to  tissue  ischemia.  Resident 
endothelial  cells  may also be a  limiting factor, having minor vasculogenic potential.  Thus, 
delivery  of  endothelial  progenitor  cells  would  be  one  strategy  to  overcome  this  problem. 
However, age, risks factors for cardiovascular disease, and diabetes are associated with reduced 
number  and  functional  activity  of  endothelial  progenitor  cells  in  the  peripheral  blood  of 
patients. Novel strategies to counteract stem/progenitor cell dysfunction in aged patients with 
coronary  artery  disease  or  diabetes  may  include  expression  of  protective  and/or  antiaging 
genes.
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Chapter 5
Nitric Oxide and Endothelial Progenitor Cells
Nitric oxide (NOˑ)  is  a gaseous second messenger with a wide range of physiological and 
pathophysiological activities. This molecule is a free radical, and can be oxidized, reduced or 
complexed with other biomolecules,  depending on the microenvironment. However,  NO is 
almost unreactive as free radical as compared to other oxygen radicals. Indeed, NO decays 
within  seconds  after  its  synthesis  if  left  unbound in  solution  because  it  reacts  with  either 
molecular oxygen or superoxide. Moreover, NO is freely diffusible across membranes. The 
molecule possesses a small dipole moment because of the similar electronegativity of oxygen 
and nitrogen, making it essentially hydrophobic.
NO does not remain as NO. -radical moiety in biological environment. In aqueous systems and 
at  air-liquid  interfaces,  NO.  -generation  yields  nitrite  (NO2-)  and  nitrate  (NO3-)  as  end 
products.  NO  generates  a  chemiluminescent  product  upon  reaction  with  ozone.  The  NO. 
-radical reacts rapidly with the superoxide radical, forming highly reactive peroxynitrite anion 
(ONOO˗) that in turn gives origin to a dangerous hydroxyl radical (93) .
NO forms complexes with transition metal ions and predominantly binds to heme group of 
proteins (94). It combines with oxyhemoglobin, which represents the principal carrier for NO 
in blood,  to produce methemoglobin and nitrate. Thus, methemoglobin levels are a useful 
index of NO production. Likewise, NO binds to the haem prosthetic group of guanylyl cyclase, 
inducing  conformational  modifications  that  lead  to  enzyme  activation.  Guanylyl  cyclase 
increases  the  production  of  cGMP, modulating  endothelium-dependent  relaxation,  platelet 
function  and  inhibitory  transmission.  Other  NO-sensitive  metalloproteins  are   cytochrome 
P450,  NADH-ubiquinone  oxidoreductase  (mithocondrial  complex  I), FADH2-succinate-Q 
reductase complex (complex II) and cytochrome C oxydase (complex III),  ferritin, myoglobin, 
cyclo-oxygenase,  catalase  and  ribonucleotide  reductase,  subsequently  inhibiting  DNA 
synthesis. 
Nitric Oxide Synthesis
Nitric oxide is produced by nitric oxide synthase (NOS), a haem containing enzyme that is 
linked to NADPH-derived electron transport (95). NOS catalyzes the oxidation of L-arginine to 
L-citrulline and NO, using tetrahydrobiopterin as an essential co-factor. 
36
There are three isoforms of NOS: endothelial NOS (eNOS, also referred to as type III NOS), 
so called since it was initially identified in bovine vascular endothelial cells, it is constitutively 
expressed  by  vascular  endothelial  cells.  It  has  a  calcium dependent  activiy  and  generates 
relatively low levels of NO. The other costitutive isoform, neuronal NOS (nNOS, type I NOS), 
first isolated in rat neuronal tissue, which mediates the transmission of neuronal signals. And 
the inducible NOS (iNOS, type II NOS), that is transcriptionally regulated by inflammatory 
cytokines  and other  stimuli.  It  is  calcium-independent  and generates  higher  levels  of  NO. 
Although nNOS and eNOS are considered to be constitutive, eNOS expression can be induced 
by different stimuli:  estrogens,  shear stress,  hypoxia, exercise,  catecholamines, vasopressin, 
bradykinin, histamin and serotonin. While nNOS expression is stimulated by pro-convulsive 
neuronal  stimuli.  Likewise,  iNOS  is  induced  by  several  stimuli,  but  also  constitutively 
expressed in certain conditions in adult and neonatal cardiomyocites, and human myocardium 
affected  by  dilatative  cardiomyopathy  (96).  Moreover,  the  three  isoforms  are  differently 
localized  at  the  subcellular  level.  The  eNOS  isoform  is  localized  in  caveolae,  uncoated 
plasmalemmal invaginations, where caveolin, the principal structural  protein,  interacts  with 
endothelial  NOS leading  to  enzyme inhibition  in  a  reversible  process  modulated  by  Ca++-
calmodulin.  nNOS is associated to sarcolemmal membranes and in the central nervous system. 
On  the  contrary, iNOS do  not  have  an  aminoacidic  sequence  suitable  for  linkage  to  cell 
membranes, and it is normally present in solution in cytosol. 
All NOS isoforms are modular enzymes (97). In intact NOS, a C-terminal reductase domain 
(which binds NADPH, FMN, and FAD) is linked to the N-terminal oxygenase domain of the 
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Fig. 8. Substrates, co-factors and products of the enzymatic reaction catalyzed by NOS. 
other monomer. The oxygenase domain carries a prosthetic heme group and can bind (6R-)
5,6,7,8-tetrahydrobiopterin (BH4), molecular oxygen, and the substrate L-arginine. 
Definition Regulation Localization
1. neuronal (type I)  >constitutive
Ca
++
/CaM dipendent
Nervous terminations, ECs and 
muscle cells
2. macrophagic (type II)  >inducible
Ca
++
/CaM indipendent
Macrophages, ECs, SMCs and 
cardiomyocites 
3. endothelial (type III)  >constitutive
Ca
++
/CaM dipendent
ECs and other cell types 
Sequences located near the cysteine ligand of the heme are apparently also involved in L-
arginine and BH4 binding. All 3 NOS isoforms possess a zinc-thiolate cluster formed by a zinc 
ion that is tetrahedrally coordinated to 2 CXXXXC motifs (1 contributed by each monomer) at 
the NOS dimer interface. Chemical removal of zinc from NOS or the possibility of expressing 
a zinc-deficient NOS that remained catalytically active demonstrated that the zinc in NOS is 
structural rather than catalytic. All NOS isozymes catalyze flavin-mediated electron transfer 
from the C-terminally bound NADPH to the heme on the N terminus. Calmodulin (on calcium-
induced binding) increases the rate of electron transfer from NADPH via the reductase domain 
flavins to the heme center. In order to synthesize NO·, the enzyme needs to cycle twice. In a 
first  step,  NOS  hydroxylates  L-arginine  to  N-  hydroxy-L-arginine  (which  remains  largely 
bound to the enzyme). In a second step, NOS oxidizes N-hydroxy-Larginine to L-citrulline and 
NO·. The flow of electrons within NOS is tightly regulated. If disturbed, the ferrous-dioxygen 
complex dissociates, and O2 is generated from the oxygenase domain instead of NO·. This is 
referred to as NOS uncoupling.
Pathophysiological Effects of Nitric Oxide
Nitric  oxide released from the endothelium, following the stimulation of endothelial  NOS, 
mediates  vasodilation  and  inhibits  platelet  aggregation.  Moreover, it  prevents  adhesion  of 
neutrophils, and expression of macrophage chemotactic protein, thereby limiting inflammation 
(98). 
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Table. 7. Nitric Oxide Synthase Isoforms.
In nervous system, NO effects are GMP-mediated. It modulates grief perception and neuronal 
plasticity,  it  is  involved  in  cerebral  development  and  short  and  long-term  learning. 
Additionally, most non-adrenergic, non-cholinergic (NANC) neurons are NO-activated via the 
same  cGMP-dependent  mechanism.  NANC nerves  subserving  important  roles  in 
gastrointestinal motility and penile erection are among those functioning through NO signals 
(99).
The immune system seems to have harnessed  the  toxic  properties  of  NO to  kill  invading 
organisms, pathogens and tumor cells. The elevated NO concentrations generated by activated 
immune cells results in widespread disruption of other biologically important iron-complexed 
proteins.  NO also  reacts  extremely  rapidly  with  superoxide  (O2-)  to  form peroxynitrite,  a 
potent oxidant with the potential to disrupt protein structures through the nitration of protein 
tyrosine  residues.  In  support  of  this  role,  nitro-tyrosine  has  been  identified  both 
immunohistochemically and analytically in the debris of tissue damaged by inflammation.
The role of NO in regulating apoptosis is controversial. Stimulation of the expression of the 
inducible form of the NO-synthase by lipopolysaccharide or inflammatory cytokines has been 
shown to induce apoptosis of several cell types, mainly macrophages. In contrast, the majority 
of the studies demonstrated an anti-apoptotic and cell protective effect of NO in endothelial 
cells. The mechanisms of NO-mediated inhibiting of endothelial cell apoptosis may include 
several transcriptional and post-transcriptional events. First, the guanylyl cyclase activation and 
cGMP release. Second, NO directly interferes with caspases, the key enzymes of apoptosis 
signaling.  Moreover, NO blocks  the  activation  of  pro-apoptotic  stress  activated  jun-kinase 
(JNK).  On the  contrary, pro-apoptotic  effects were mainly  observed in  macrophages.  This 
could be explained by the the fact that eNOS generates only low concentrations of NO, with 
an  anti-inflammatory  and  anti-apoptotic  effects,  whereas  higher  concentrations  iNOS-
generated would result in apoptosis. 
Role of eNOS in Neovascularization
The NO produced by eNOS mediates a variety of physiological functions in vivo including 
neovascularization, regulation of blood vessel tone, platelet aggregation, vascular permeability 
and leukocyte-endothelial interactions.  In addition to NO, more than 20 angiogenic factors 
have been individuated in the recent years, such as vascular endothelial growth factors (VEGF-
A, B, C, D and E),  placental-derived growth factor (PIGF),  platelet-derived growth factors 
(PDGF-A, B, and C), fibroblast growth factors (FIGF-1 and 2), transforming growth factors 
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(TGF-α  and β),  hepatocyte growth factor (HGF), platelet derived endothelial growth factor 
(PD-EGF), tumour necrosis factor α (TNFα), interleukin-8 (IL-8), angiopoietins (Ang-1 and 2) 
and sphingosine 1-phosphate (S1P). However, NO does not only induces endothelial migration 
and proliferation,  but  also modulates  the effects of many of  the growth factors  mentioned 
before. 
VEGF  is  one  of  the  most  potent  angiogenic  factors  and  activates  eNOS.  The  interaction 
between VEGF and NO has a major role in vascular permeability, vessel tone and angiogenesis 
during  inflammation,  wound  healing  and  tumor  growth.  A selective  modulation  of  eNOS 
activity  would  represent  an  attractive  strategy  for  altering  angiogenesis  and  vascular 
permeability (100).
eNOS  plays  an  important  role  also  in  another  type  of  neovascularization,  the  postnatal 
vasculogenesis, which involves EPCs. In their study, Aicher and coworkers examined the effect 
of eNOS on EPC effectiveness in neovascularization (73). They reported that NOS3-/- mice had 
defective  hematopoietic  recovery and progenitor  cell  mobilization,  resulting  into  increased 
mortality  after  myelosuppression  and  reduced  VEGF-induced  mobilization  of  EPCs. 
Intravenous infusion of wild type EPCs rescued the impaired neovascularization of  NOS3-/- 
mice in a model of hind-limb ischemia. NOS3-/- mice presented a profoundly reduced activity 
of  pro-MMP-9.  In  fact  MMP-9 activation  by  NO is  a  crucial  event  for  cell  mobilization. 
Furthermore,  the restored neovascularization after  infusion of wild-type cells  indicates that 
eNOS is also required at the site of vessel formation. 
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Fig. 9. Upstream signalling events leading to the induction of neovascularization by nitric oxide.
Role of iNOS in Neovascularization
Recently also the potential importance of iNOS in neovascularization has been investigated. 
The  study  by  Mayr  et  al  reported  a  central  role  for  the  inducible  NOS  in  vein  graft 
reendothelization  by  circulating  progenitor  cells  (CPCs)  (101).  In  fact,  they  observed  that 
deletion  of  the  iNOS  gene  resulted  in  enhanced  neointima  formation,  attenuated 
reendothelialization by CPCs,  and attenuated production of the vascular endothelial growth 
factor  (VEGF). Conversely,  the  application  of  VEGF  in  iNOS-/-  mice  promoted 
reendothelialization and prevented neointima formation. This demonstrated that the induction 
of VEGF in the vein graft occurs via a pathway involving NO and that VEGF plays a central 
role for reendothelialization by CPCs. Having the CPCs and the SMCs the same origin, NO 
would switch cell differentiation toward an endothelial phenotype, inhibiting the synthesis and 
the action of smooth cell growth factors. 
Losordo  et  al.  studied  the  EPC  contribute  to  cardioprotective  effects  of  ischemic 
preconditioning, and showed the importance of both endothelial and inducible NOS activity in 
these cells (91). Precisely, their study pointed out that repeated short ischemic periods (IP) 
enhanced EPC mobilization,  recruitment  and homing in  the  myocardial  tissue.  Myocardial 
protection by EPCs is affected by cell incorporation in vascular structures, but also by eNOS, 
iNOS activity. By using bone-marrow cells originated from eNOS-/- o iNOS-/- donors, it has 
been shown that cardiac protection depends on eNOS or iNOS according to the ischemic insult 
used on heart.
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Fig. 10. Putative mechanisms leading to the reendothelization of vein grafts by circulating progenitor cells. 
(Brandes RP. 2006)
Nitric Oxide and Diabetes
Being NO important for the regulation of EPC mobilization and function, it has been studied 
the role of NOS isoforms in diabetic EPC dysfunction. Impairments in eNOS function have 
been reported with hyperglycaemia, insulin resistance, and in peripheral tissue from diabetic 
patients (102). Therefore, it has been studied if eNOS function in diabetic bone marrow cells is 
altered. It has been observed enhanced eNOS expression in the bone marrow of diabetic rats, 
whereas eNOS monomerization and superoxide anion production were increased (103).  By 
using  NOS inhibitors,  superoxide  anion was blocked.  This  suggested  that  probably it  was 
occurred  the  eNOS  uncoupling,  which  had  previously  been  linked  to  the  enzyme 
monomerization. As a consequence, NO bioavailability in bone marrow is reduced.  
Moreover,  NO  seems  to  be  involved  in  insulin  response  to  arginine.  In  the  past  years, 
accumulating evidences suggested that arginine could influence insulin secretion in a complex 
way, by  exterting  a  metabolic  action  based  on  its  monooxygenation  by  NOS.  Indeed,  the 
constitutive neuronal isoform, nNOS, has been characterised in rat pancreatic islets and β-cell 
lines (104). It is implicated in an inhibitory modulation of insulin secretion in experiments 
mainly  based on the  use of  pharmacological  NOS inhibitors,  such as  N-ω-nitro-L-arginine 
methyl ester (L-NAME). In a diabetic model obtained by combined injection of streptozoticin 
(STZ) and nicotizamide (NA), L-NAME markedly enhanced arginine-induced insulin release. 
Furthermore, exposure of diabetic islets to the NOS inhibitor failed to modify their response to 
arginine.  This  could be  due  to  either  a  decreased  nNOS expression in diabetic  islets  or  a 
reduced activity of the enzyme (105).    
In addition, in their study Bradley at al.  demonstrated that patients with prediabetes/type 2 
diabetes have 35% to 40% lower skeletal nNOS protein expression (106) and elevated iNOS 
levels. A higher  iNOS expression could the consequence of the inflammatory status set in 
diabetes. It would be also involved in the blood retinal barrier breakdown in the early stages of 
retinopathy, through a ICAM-1 upregulation and tight junction downregulation (107).      
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Chapter 6
ROS and Endothelial Dysfunction
It is now widely recognized that an increase in oxidative stress denotates an imbalance between 
reactive  oxygen  species  (ROS)  production,  such  as  superoxide  and  H2O2,  and  antioxidant 
species, and plays an important role in the genesis of the dysfunction in endothelial phenotype. 
As previously described, the principal mechanism underlying ROS-dependent impairment of 
endothelium-mediated  vasorelaxation  is  the  inactivation  of  NO,  with  a  reaction  that  also 
generates  peroxynitrite.  Interestingly,  oxidative  stress  leading  to  endothelial  vasodilator 
dysfunction is also a predictor of adverse outcome in patients with coronary artery disease 
(108). In addition to the interaction with NO, ROS have important direct effects through the 
modulation of diverse redox-sensitive signalling pathways in endothelial cells which influence 
gene and protein expression and may have an impact on many different functions. Among 
these  functions,  there  are  endothelial  cell  growth,  proliferation,  migration,  survival, 
cytoskeletal  reorganisation, cell  shape,  adhesion molecule  expression,  permeability and the 
secretion  of  inflammatory  cytokines.  There  are  several  potential  sources  of  superoxide  in 
endothelial cells, including mitochondria, cytochrome P450-based enzymes, uncoupled eNOS, 
xanthine oxidase and NADPH oxidases. Among these sources, NADPH oxidases represent the 
only enzymes whose primary function is ROS generation. Moreover, NADPH oxidases are 
specifically activated by many of the stimuli that are known to cause endothelial dysfunction 
and activation and they can be considered the major ROS source in endothelial dysfunction and 
redox signalling. Recently, these enzymes have even been found to be important  in  signal 
transduction pathways involved in angiogenesis and neovascularisation (109). 
Furthermore, an important attribute of the NADPH oxidases is their potential to augment ROS 
generation by other enzymes. For example, NADPH oxidases can cause uncoupling of NOS, 
secondary to oxidative degradation of the NOS cofactor tetrahydrobiopterin (H4B), thereby 
leading to superoxide rather than NO generation. 
NADPH oxidase
The NADPH oxidase complex was first described in neutrophils where it is involved in non-
specific host defence against microbes ingested during phagocytosis, through the generation of 
large quantities of superoxide and protons (110). The phagocytic oxidase is composed of two 
membrane-associated subunits, p22phox and gp91phox, which form a flavocytochrome (cyt 
b558). The process of electron transfer from NADPH to molecular oxygen, which results in 
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superoxide  formation,  is  catalysed  by  the  oxidase  following  its  activation  through  the 
translocation of several cytosolic regulatory subunits (p47phox, p67phox, p40phox and Rac), 
which associate with cytochrome b558. 
Components of the NADPH oxidase were found to be present in many nonphagocytic cells, 
including  VSMC  (111),  endothelial  cells  (112),  adventitial  and  cardiac  fibroblasts,  and 
cardiomyocytes  (113).  Because  of  different  biochemical  activity  of  the  phagocytic  and 
nonphagocytic oxidase, a whole family of NADPH oxidases has been identified basing on 
distinct homologues of gp91pho. The Nox family may be classified into two groups, based on 
predicted  domain  structures:  (i)  Nox1-4  all  contain  six  transmembrane  domains  and  have 
NADPH and FAD-binding domains at the cytoplasmic C-terminus; (ii)  Nox5 has a similar 
basic structure but with an additional N-terminal calmodulin-like Ca2+-binding domain. 
In addition, two related oxidases, Duox1 and 2, include a further N-terminal extension with a 
peroxidase-homology domain that is separated from the Ca2+-binding domain by an additional 
transmembrane segment. The expression of these different Nox isoforms varies according to 
cell and tissue. Nox2 and Nox4 are co-expressed in endothelial cells, although there are a few 
reports that Nox1 and Nox5 might also be present in some settings. In homogenates of human 
arteries and veins Nox2 mRNA expression was higher than that of Nox4  (114). These two 
isoforms are probably regulated by different stimuli and may play distinct roles in endothelial 
cells through expression in different subcellular locations.
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Fig. 11. Schematic diagram of the different NADPH oxidase isoforms (Dworakowski R. et al, 
2008). 
NADPH oxidases and Endothelial Dysfunction
A significant  body  of  evidence  implicates  NADPH  oxidase  activation  in  the  endothelial 
dysfunction  mechanisms,  like  the  up-regulation  of  cell  surface  adhesion  molecules, 
chemokines,  and an increase in permeability. TNF-α and other pro-inflammatory cytokines 
increase the expression of ICAM-1, VCAM-1 and MCP-1 in an nuclear factor- B (NF- B) 
dependent manner via the activation of Nox2 (115). Angiotensin II-induced stimulation of the 
AT1 receptor is a potent agonist for activation of the Nox2 oxidase in endothelial cells.
Shear  stress  results  in  several-fold  induction of  Nox1,  Nox2,  and  Nox4. Nox1  expression 
increases  3-fold  following  balloon  injury  and  precedes  restenosis  and  atherosclerosis.  ? In 
addition,  both tissue  hypoxia  and VEGF may be  important  stimuli  for  Nox2 activation in 
neovascularization,  and  an  involvement  of  this  isoform  in  ischemia-induced  and  VEGF-
induced neovascularisation has been confirmed in vivo (109).
In  diabetes  mellitus,  chronic  hyperglycemia  involves  biochemical  abnormalities  including 
increased  polyol  pathway  flux,  increased  formation  of  advanced  glycation  end  products 
(AGEs), activation of protein kinase C, and increased flux through the hexosamine pathway. 
All these pathways seem to result from overproduction of ROS (116), and antioxidants are 
protective against deleterious effects of high glucose levels on vascular endothelial cells. Nox 
enzymes, particularly the Rac-regulated enzymes Nox1 and Nox2, play a role in endothelial 
dysfunction in the setting of diabetes mellitus (117). Some of the  cardiovascular pathologies 
seen in diabetes may be mediated by the glycated proteins that result from high glucose levels. 
An example is the Nox2-dependent ROS production stimulated by  glycated BSA.
Moreover, Nox1, Nox2, and Nox4 seems to be important in insulin secretion mechanisms. 
They had been found in pancreatic islet  cells  and glucose-stimulated insulin secretion was 
suppressed by a general Nox inhibitor, supporting the hypothesis of a role for one or more Nox 
enzymes in normal pancreatic islet function (118). Despite this functional role of Nox, it has 
been conceived an involvement of these enzymes in diabetes progression. An excessive ROS 
production may damage pancreatic islets leading to type 1 diabetes. In early type 1 diabetes, 
systemic  markers  of  oxidative  stress  correlate  with  insulin  requirements,  suggesting  that 
oxidative stress in the pancreatic islet leads to damages in insulin-secreting beta-cells (119). In 
type II diabetes, increased expression of Nox1 occurs in islets, and may exacerbate disease 
over time by damaging insulin-producing cells (120).
The Nox2 could have a dual role by promoting endothelial cell activation as well as inhibiting 
it, although the precise mechanisms underlying these opposing effects remain unknown.
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Chapter 7
Aim of the study
Better  understanding  the  mechanisms of  impaired vascular  repair  has  clinical  relevance in 
cardiovascular  and  peripheral  arterial  disease.  The  endothelial  progenitor  cells  have  an 
important role in vascular homeostasis  and actively participate to vasculogenesis. Thus, an 
impaired cell  function is  associated with endothelial  dysfunction and vascular disease. The 
long term goal of this study is a possible improvement of cell-mediated vascular repair in those 
individuals who present a reduced endothelial progenitor cell availability and activity, in order 
to improve the effectiveness of vein graft transplantion. To this end, it has been investigated the 
functional changes underlying the EPC dysfunction in patients with peripheral arterial disease. 
The first  aim has been the study of the proliferation,  differentiation and function of EPCs 
derived from healthy volunteers. Given the role of NO in endothelium homeostasis, it has been 
studied the expression of NOS isoforms, and the effect of NOS inhibition. Moreover, due to the 
ROS dependent NO inactivation, it has been considered the expression of NADPH oxidases.  
Secondly, in  order  to  evaluate  the  effects  of  diabetic  hyperglicaemic conditions  on  EPCs, 
isolated cells were cultured at elevated glucose concentration, considering the possible changes 
in cell proliferation and function. 
The third aim has been the study of EPCs derived from patients affected by peripheral arterial 
disease,  whether  diabetic  or  not,  in  terms  of  proliferation,  differentiation,  and  function. 
Furthermore,  it has also been assessed if functional changes may subsist in any difference in 
NOS and NAPDH oxidase expression.  
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Chapter 8
Materials and Methods
Peripheral Blood Samples
Endothelial progenitor cells were isolated from peripheral blood samples, both from healthy 
subjects and from patients with PAD. 
Blood samples from healthy human adult  volunteers of both genders were supplied by the 
Service of Transfusion Medicine of S. Orsola-Malpighi Hospital of Bologna (Italy). 
In this study 21 patients were recruited at the Vascular Surgery Unit of the S. Orsola-Malpighi 
Hospital of Bologna (Italy). All patients were affected by peripheral arterial occlusive disease, 
and  critical ischemia. Most of patients had a IV stage disease, affecting various vascular beds, 
mainly femoropopliteal artery. 70% of patients recruited for this study suffered from type 2 
diabetes.   
Determination of Circulating Endothelial Cell Number in Patient Samples
For this analysis it was used  CELLQUANT FF-CD146 kit (BIOCYTEX Marseille France). 
This kit is based on CD146 cell enrichment by immuno-magnetic separation from total blood 
samples and successive count of circulating endothelial cells (CECs).
Sample Preparation.  For each sample, 2 mL of total blood were divided into two vials each 
containing 1 mL of diluent solution and 50µL of CD146-coated magnetic microspheres. After 
two cycles of magnetization and homogenization, respectively of 5 and 20 min, that allow cells 
to interact with coated antigenes, supernatant was removed so that to eliminate CD146 negative 
cells. 1mL lysis reagent was added to the pellet, in order to lyse red blood cells, that could 
interfere with the analysis. In the control vial, enriched cell suspension was added with CD45 
monoclonal  antigen  conjugated  with  FITC.  In  the  second  one,  both  CD45  and  CD146 
conjugated with phicoerythrin (PE) antigens were added. After 10 min incubation, cells were 
fixed and marked microspheres were added. 
Cytofluorimetric  Analysis.  Analysis  were  performed  by  using  the  FC500  cytofluorimeter 
(Beckman-coulter). Cells from healthy subjects was used as control.  
The number of cells detected in each vial was expressed by the ratio of cells in D region to 
cells in region C. Number of CD146 positive cells was obtained by the difference between the 
number of cells detected in the first vial (CD45 cells) and the number of cells detected in the 
second vial (CD45 and CD146 cells). 
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Cell Culture in Hyperglycaemic Conditions
In order to study the effects of high glucose concentration,  cells were cultured in medium 
additioned with glucose, at a final 22 mM glucose concentration (121). As a control, cells were 
cultured  in  a  medium with  a  normal  glucose  concentration  (5,5  mM),  but  with  the  same 
osmolarity of high glucose concentration medium, by adding mannitol 16,5 mM.
Cell Viability
Cell proliferation was evaluated by 3-[4,5-dimethylthiazol-2-]-2,5-dipheniltetrazolium bromide 
(MTT) viability assay, which is based on the reduction by living and early apoptotic cells of 
MTT salt into insoluble purple formazan crystals, which are  solubilised by the addition of a 
detergent. The  coloured  salt  production  can  be  quantified  by  spectrophotometric  means, 
measuring  the  absorbance  of  the  solution.  The  number  of  surviving  cells  is  directly 
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   Fig. 12. Number of CECs detected by cytofluorimetry.
proportional  to  the level  of  the formazan.  Cells  were plated in  96-well  plates  coated with 
human fibronectin, and kept in culture for 10 days. MTT assay was performed at 3, 7 and 10 
days  of  culture.  The  quantification  of  formazan  crystals  was  obtained  by  measuring  the 
absorbance of the cell solution at 500 nm by using a VICTOR2 1420 Multilabel Counter.
Morphological Characterization
Adherent cells were observed with phase contrast inverted microscope Olympus IX50. Cells 
which presented a spindle shape were considered as differentiating EPCs.
In order to evaluate cell differentiation, cells were counted at different culture time (3, 7, and 
10 days) in five different fields per Petri dish, with a 20X magnification. It was considered the 
total number of cells and the number of spindle shaped cells.   
Cellular Staining and AcLDL Uptake
Adherent cells resulted positive to double-fluorescence staining for Dil-labeled acetylated low 
density  lipoprotein  uptake  (acLDL, Moleculare  Probes)  and FITC labeled  Ulex Europaeus 
agglutinin binding (FITC UEA-1, Sigma-Aldrich) were identified as early EPCs.
Briefly, direct fluorescent staining was used to detect the binding of fluorescein isothiocyanate 
(FITC) - labeled  Ulex Europaeus agglutinin (UEA-1, Sigma, St. Louis, Missouri, USA) and 
cell uptake of 1,1-dioctadecyl-3,3,3,3-tetramethilindocarbocyanine (Dil) – labelled acetylated 
low  density  lipoprotein  (acLDL,  Molecular  Probes,  Eugene,  Oregon,  USA).  Cells  were 
incubated with 10 µg/ml acLDL for 4 h, and 10 µg/ml UEA-1, for 2 h, at 37 °C and fixed with 
3% paraformaldehyde for 15 min. Cells with double-fluorescent staining were identified as 
differentiating EPCs and their average number per field was evaluated counting 10 randomly 
selected high-power fields (20x) under an inverted fluorescent microscope (IX50 Olympus). 
HUVECs were chosen as positive controls either for direct fluorescence staining (Dil-acLDL, 
FITC-UEA-1). More than 85 % of HUVECs was positively stained for the above-mentioned 
endothelial markers. 
Vasculogenesis Assay
The  vasculogenic  capacity  was  determined  by  the  de  novo  vessel  formation  in  a  three-
dimensional  gel.  96-well  tissue  culture  plates  were  coated  with  Matrigel  Matrix  (Becton 
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Dickinson) that polymerizes at 37 °C to produce biologically active matrix material resembling 
the mammalian cellular basement membrane. Therefore, two week cultured EPCs were plated 
alone (20000 cells/well) or co-cultured with HUVEC (10000 cells/well HUVEC plus 10000 
cells/well EPCs). Cells were incubated at 37°C for 24 h and tubule formation was observed 
under an inverted light microscope IX50 Olympus at 10X magnification. 
When plated together with HUVECs, EPCs were previously labelled with Ac-LDL-Dil for 4 h 
in order to allow the identification of the two populations.
NO Metabolism
NO Production
Intracellular NO production was determined by using Diaminofluorescein –2 Diacetate (DAF-
2DA) is a non-fluorescent cell permeable reagent.  It can measure free  nitric oxide in living 
cells under physiological conditions. Once inside the cell the diacetate groups on the DFA-2DA 
reagent  are  hydrolyzed  by  cytosolic  esterases  thus  releasing  DAF-2  and  sequestering  the 
reagent inside the cell.  Nitric oxide produced by the cell converts the non-fluorescent dye, 
DAF-2, to its fluorescent triazole derivative, DAF-2T, that can be observed by exciting the 
reagent at 488nm and then measuring the emission at 515nm. 
EPCs at 14 day culture were plated in 96-well plates and treated with NOS inhibitors: NG-nitro-
L-arginine methyl ester hydrocloride (L-NAME) (Sigma) 100 mM; N6-(1-Iminoethyl)-L-lysine 
dihydrocloride  (L-NIL)  (Alexis  Biochemicals)  20  µM,  and  N5-(1-Iminoethyl)-L-ornithine 
dihydrocloride  (L-NIO)  (Alexis  Biochemicals)  10  µM. Thereby, after  48  hours  cells  were 
incubated with DAF-2/DA 10 µM (Sigma) diluted in a buffer solution containing [mM] NaCl 
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Fig. 13. Mechanism of DAF-2DA conversion to the fluorescent molecule DAF-2T.
Fluorescence
142, KCl 2, K2HPO4 1.2, MgSO4 1, HEPES 10, CaCl2 1.3, and glucose 10,  at  37 °C for 30 
minutes.  Emission  fluorescence  was  measured  with  a  VICTOR2  1420 Multilabel  Counter 
(Perkin Elmer).
NO and Cell Proliferation
Cells  were  plated  into  96-well  plates  coated  with  human fibronectin  at  a  density  300000 
cell/cm2. Cells  were  treated  with  NOS  inhibitors,  NG-nitro-L-arginine  methyl  ester 
hydrocloride (L-NAME) (Sigma) 100 mM, N6-(1-Iminoethyl)-L-lysine dihydrocloride (L-NIL) 
(Alexis  Biochemicals)  20  µM,  and  N5-(1-Iminoethyl)-L-ornithine  dihydrocloride  (L-NIO) 
(Alexis Biochemicals) 10 µM and kept in culture for 10 days. Cell proliferation was assessed 
by MTT assay at 3, 7, and 10 days of culture.  
NO and Vasculogenesis
Cells  were  pretreated  with  NOS  inhibitors,  L-NAME  (Sigma)  100  mM,  L-NIL(Alexis 
Biochemicals) 20 µM, and L-NIO10 µM and kept in culture for 12 days. At day 13 cells were 
seeded  together  with  HUVECs  in  96-well  plates  coated  with  Matrigel  Matrix  (Becton 
Dickinson),  as  previously  described. Cells  were  incubated  at  37°C  for  24  h  and  tubule 
formation  was  observed  under  an  inverted  light  microscope  IX50  Olympus  at  10X 
magnification. 
Quantification of NOS mRNA Expression by Real-Time PCR
The assay for mRNA expression of NOS isoforms was optimized for the Light Cycler version 
3.5 (Roche Molecular  Biochemicals,  Mannheim,  Germany),  with a Real  Time-PCR in two 
steps.  RNA  extraction  was  performed  by  using  High  Pure  RNA  Isolation  Kit  (Roche 
Diagnostics, Mannheim, Germany) and, for smaller samples, RNAqueous-Micro Isolation Kit 
(Ambion, Texas, USA). The reverse transcription was performed by using Transcriptor First 
Strand  cDNA Synthesis  Kit  (Roche  Diagnostics,  Mannheim,  Germany)  according to  the 
manufacturer’s  instructions. NOS mRNA expression  was  quantified  relative  to  the  β-actin 
housekeeping gene. The primer sequences were as follows: β-actin, sense 5'-CCA GAG GCG 
TAC AGG GAT AG-3' and antisense 5'-CCA ACC GCG AGA AGA TGA-3' (122). eNOS, 
sense 5'-CCG GGT ATC CAG GTC CAT-3' and antisense 5'-GAC CCT CAC CGC TAC AAC 
AT-3' (123); iNOS, sense 5'-TGG CCA TCC TCA CAG GAG-3' and antisense 5'-CAA AGG 
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CTG TGA GTC CTG CAC-3' (124). nNOS, sense 5'-CCG CGC TTA CAA ACT TGC-3'  and 
antisense 5'-TGA GTC CAT TGC CTT CAT TG-3'; PCR fragment of 424 bp (125). Real-time 
PCR was performed in Light Cycler capillaries using a master mix containing TaqMan DNA 
polymerase and  the respetive probes for each NOS type mRNA (LightCycler TaqMan Master, 
Roche Molecular Biochemicals). DNA fragment amplification was performed after the addition 
to the master mix of primers (final concentration: 0.5 µM) and template cDNA (10 to 100 ng). 
The protocol was the following: 1 cycle at 95 °C for 15 min for the initial enzyme activation, 
then 45 cycles of denaturation (94°C for 10 s), annealing (60 to 63°C for 10 s) and extension 
(72°C for 6 to 15 s). In order to verify the purity of the products, a melting curve was produced 
after the completion of each PCR amplification by increasing the temperature of the reaction 
mixtures up to 95 °C, by 0.1 °C/s, starting at 60 °C for 60 s. 
The Roche software used the second derivative maximum method to calculate the fractional 
cycle  numbers  where the fluorescence  rises  above background at  the  fastest  rate  (crossing 
point,  Cp).  The amount of mRNA was calculated according to Pfaffl (2001) relative to the 
housekeeping gene  β-actin. All the values were normalised to the corresponding mRNA of 
NOS isoforms expressed by HUVECs at passages between 3 and 6.
NOS Protein Expression
Whole protein extract (80 µg/sample) was prepared from MNCs and EPCs (1 x 107 cells/ml) at 
7,  14 and 21 days of culture.  The samples were electrophoresed by 7.5% sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) (1 h, 150 V) and blotted (1 h, 100 V) 
onto nitrocellulose membranes (Bio-rad, CA, USA). After ishing in TBS-Tween (10 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 0.05 % Tween-20), the membranes were treated for 1 h with 5 % 
non-fat dry milk (Bio-rad, CA, USA) to block non-specific binding sites. The membranes were 
incubated for two hours with rabbit polyclonal antibodies for iNOS (NOS2), eNOS (NOS3), 
and nNOS (NOS1) (Santa Cruz, Biotechnology, Europe) diluted 1:1000 in TBS-Tween. The 
immune reaction was revealed by a peroxidase-labelled goat anti-rabbit antibody (Santa Cruz, 
Biotechnology, Europe) diluted 1:2500 in TBS-Tween. The secondary antibody was added to 
membranes for 1 h at room temperature, followed by 1 min exposure with the Luminol reagent 
(Santa  Cruz,  Biotechnology, Europe)  which  was  revealed  by  high-sensitivity  photographic 
film. β-actin was used as internal control.
Silencing of iNOS by Small Interfering RNA (siRNA)
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To obtain  inactivation  of  iNOS,  cells  were  transiently  transfected  by  siRNA Transfection 
Reagent (Santa Cruz) with iNOS siRNA. The sequence for iNOS was CCA GAG GAG CTT 
CTA CTT CAA (125), sense primer was 5'-rArCrArArCrArGrGrArArCrCUrArCrCrArGrC TT 
and antisense primer 5'-rGrCUrGrGUrArGrGUUrCrCUrGUUrGU TT. Cells were plated 7 x 
106/mL in 60 mm dish plates and cultured under normal growth conditions for 3 days. At day 4 
cells were washed with medium and then incubated with 1500 µL siRNA Transfection Medium 
added with siRNA Transfection Reagent 10 µL and diluted siRNA 50-100 pmol/µL for 5 h at 
37 °C. Then M199 medium with 20% FBS was added to the transfection mixture and cells 
were incubated  for additional 18-24 h before removing it. Then medium was aspirated and 
replaced with normal M199 with 10% FBS and growth factors.   
Quantification of NADPH Oxidase mRNA expression by Real-Time PCR
The assay for mRNA expression of Nox1, Nox2, and Nox4 was performed by the Light Cycler 
version 3.5 (Roche Molecular Biochemicals,  Mannheim, Germany),  with a RT-PCR in two 
steps.  RNA extraction  was  performed  (Roche  Diagnostics,  Mannheim,  Germany)  and,  for 
smaller  samples,  RNAqueous-Micro  Isolation  Kit  (Ambion,  Texas,  USA).  The  reverse 
transcription was performed by  using Transcriptor First Strand cDNA Synthesis Kit (Roche 
Diagnostics,  Mannheim,  Germany)  according to  the  manufacturer’s  instructions. mRNA 
expression was quantified relative to the  β-actin housekeeping gene. The primer sequences 
were  as  follows:  β-actin,  sense  5'-CCA GAG GCG TAC AGG GAT AG-3' and  antisense 
5'-CCA  ACC  GCG  AGA  AGA  TGA-3'  (122).  Nox1,  sense 
5'-TTTGGATGGGTGCATAACAA-3' and  antisense  5'-AAGGATCCTCCGGTTTTACC-3' 
(127); Nox2,  sense  5'-CGATGGTTTTGAAAGGTTGA-3' and  antisense 
5'-GGTTTTGGCGATCTCAACAG-3' (128). Nox4, sense 5'-CCG CGC TTA CAA ACT TGC-
3' and antisense 5'-TGA GTC CAT TGC CTT CAT TG-3' (127). Real-time PCR was performed 
as described before.
Statistical Analysis
Statistical Analysis was performed with a Student's test and results are expressed as mean± 
SEM. Probability values of P<0.05 were considered statistically significant.  
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Chapter 9 
Results
AIM I: Study of EPCs derived from healthy subjects and the role of NO. 
Culture of EPCs 
Mononuclear cells from healthy volunteers were plated under differentiating conditions at  a 
concentration 106 cells/mL and kept in culture for 14 days. Soon after plating, cells presented a 
round shape and low attaching ability, but,  from the 3rd day on, it was possible to observe 
spindle-shaped and attaching cells (AT cells).  Their number increases throughout the days of 
culture,  and cells  begin to have a mature endothelial  cell-like aspect,  also referred to as a 
typical cobblestone-aspect.  
If  plated at  higher concentrations,  these cells  tended to  join  together, forming the  clusters 
described in literature. 
 
Functional characterization
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A B C
Fig. 14. Morphological changes of EPCs during the differentiation process. (A) cells at the 3rd day of 
culture: only few AT cells are detectable; (B) cells at the 7th day: AT cell number is considerably increased. 
(C) day 10: cells begin to have a morphology more similar to mature endothelial cells. 
A B
Fig. 15. Evolution in EPC morphology. Already from the 7th day of culture, it is possible to observe cell 
agglomerates, called clusters (a). The clusters represent the colonies of CFU-cells who give rise to the late 
endothelial precursors.   
In  order  to  confirm  the  differentiation  toward  an  endothelial  phenotype,  cells  were 
characterized by Dil-Ac-LDL uptake and UEA-FITC binding. Then, they were observed at 
inverted light microscopy and it was counted the number of cells who had incorporated Dil-
AcLDL,  cells  who  had  bound  UEA-FITC,  and  cells  who  were  positive  for  both 
characterizations.  Only  these  cells  were  considered  as  EPCs  differentiating  toward  an 
endothelial phenotype. 
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Fig. 18 a, b, c, d. Characterization of EPCs by Ac-
LDL uptake and UEA-FITC binding. Data are 
expressed as the percentage of cells positevely 
stained to the total amount of cells. a) Cells 
positive for Dil-acetylated LDL uptake. b) Cells 
positive for UEA-I binding. c) cells positive to 
both characterizations. 
Fig. 16. Characterization of endothelial progenitor cells. Cell nuclei were labelled with 4',6-diamidino-2-
phenylindole (a). Therefore, cells were both stained with Dil-AcLDL (b) and UEA-FITC (b). 
a b c
Fig. 17. Trend of EPC characterization. 
Cells were plated on fibronectin coated 
plates and the characterization of 
differentiating cells was assessed by 
double staining with Dil-acLDL uptake 
and UEA-FITC binding. Already from 
the 2 day of culture a high rate of cells 
was positive to staining, and could be 
considered as EPCs.
Already  after  2  day  culture,  MNCs  appeared  to  be  positive  to  EPC  characterization. 
Differentiated mononuclear cell population should have at  least 80 % of positively stained 
cells. 
Moreover, another functional characterization so that to verify endothelial differentiation was 
the vasculogenesis assay. Cells were cultured for two weeks, then plated in Matrigel coated 
plates and incubated for 24 hours. As observed at inverted light microscopy, EPCs did not 
present the same vasculogenic ability the mature endothelial cells have. After 24 hours, no tube 
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Fig.20. Incorporation of EPCs in capillary-like structures formed by HUVECs. EPCs were previously 
labelled with Dil-AcLDL and incubated for 24 h in Matrigel coated plates together with HUVECs. 
Afterward they were observed under inverted light microscope, at 10X and 20X magnification. It was 
evident that EPCs actively participated to HUVEC tube formation.   
Fig. 19. EPCs vasculogenic ability. EPCs 
were marked with AcLDL and cultured for 24 
hours on a Matrigel layer. Tube formation was 
observed under fluorescence inverted light 
microscopy. EPCs were not able to form new 
vessels ex novo , even if an approssimative 
capillary-like structure was observed
10 X
20 X
10 X
20 X
formation  was  observed.  Cells  tended  to  form  agglomerates,  and  eventually  assume  an 
approssimative  capillary-like  structure.  Albeit  EPCs  showed  little  vasculogenesis  ability  if 
cultured  alone,  they  were  able  to  participate  to  vasculogenesis  carried  out   by  mature 
endothelial  cells,  such  as  HUVECs.  EPCs,  previously  labelled  with  AcLDL,  were  plated 
together with HUVECs on Matrigel monolayer. Labelled EPCs were visibly inserted in the 
new  capillary  like  structures  created  by  HUVECs,  thereby  giving  an  evidence  of  EPC 
involvement in postnatal neovascularization. 
Role of NO in EPC function
Being the NO essential for neovascularization, it has been investigated if lower vasculogenic 
potential of EPCs could be referable to a lower NO synthesis. Firstly, it was assessed if EPCs 
were able to produce NO. Cells were labelled with the selective probe DAF-2DA and observed 
under fluorescence light microscopy (fig. 21). Hence, it has been studied the expression of 
NOS isoforms and the effects of NOS inhibition on EPC differentiation and function.
NOS expression
Regarding the  protein levels of  NOS isoforms,  cell  lysates were analysed by western blot 
technique. While HUVECs presented high levels of eNOS and low levels of nNOS, these two 
isoforms had not  been  detected  in  EPCs.  Except  for  iNOS,  whose expression in  EPCs is 
detectable by Western blot, the eNOS and nNOS protein concentrations are presumably to low 
to be detected.   
NOS isoforms MNCs EPCs HUVECs
eNOS - - ++
nNOS - - +
iNOS - + -
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Tab. 10. Expression of NOS proteins. eNOS and nNOS had not been detected by Western Blot in EPCs, 
probably because of too low concentration of these two enzymes in EPCs. As positive control it was used 
an extract of HUVECs. (-) no protein detected by Western Blot analysis. (+) protein detected by Western 
Blot. 
Fig. 21. Production of NO. Cells 
were incubated with non 
fluorescent probe DAF- 2DA 
that in presence of NO gives 
origin to a fluorescent molecule.
Being NOS proteins fairly undetectable by Wester Blot, it had been chosen a more sensible 
method, based on mRNA quantification. It was assessed the expression of eNOS mRNA and 
iNOS mRNA in  MNCs culture  under  normal  condition  (control)  and under  differentiating 
condition (GF).  eNOS mRNA is poorly expressed in EPCs, compared to mature endothelial 
cells  (only  5%  of  eNOS  mRNA in  HUVECs).  However  its  expression  increases  in  cells 
cultured under differentiating conditions, suggesting that cells are differentiating towards an 
endothelial phenotype. On the contrary, iNOS mRNA levels in differentiated EPCs are 2-3 fold 
higher than in HUVECs , confirming data obtained thanks to Western Blot analysis.
An ulterior confirmation of NOS pattern in EPCs was obtained by selectively inhibiting the 
three isoforms and subsequently measuring NO production with the fluorescent probe. In fact, 
iNOS inhibition with L-NIL resulted in the lowest NO production. 
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Fig. 22. Levels of mRNA coding for NOS 
isoforms.  Values are expressed as a ratio of 
mRNA of EPCs to the mRNA of a reference 
cell type, such as HUVECs, mRNA is 
expressed via a formula, 2(10-Δcp)x105  in 
which ΔCp is the difference between the Cp 
of studied gene and the Cp of the 
housekeeping gene. Ctrl: cells cultured with 
normal M199, Gf: cells cultured under
differentiating growth factors. 
Fig. 23. Measure of NO production with DAF-2DA. 48 h before analysis, cells were treated with NOS 
inhibitor  L-NAME (1 mM), iNOS specific L-NIL (100µM) and eNOS specific L-NIO (10 µM). Then, they 
were incubated for 30 min at 37 °C with DAF-2DA 10 µM. Fluorescence was measured with a 
spectophotometer. 
NO and proliferation
The second aim was to evaluate how nitric oxide influences EPC function. Hence, the first step 
was studying its effect on endothelial  cell proliferation. HUVECs were cultured with NOS 
inhibitor for 10 days, and cell viability was measured by MTT assay at different culture time.  
Inhibition  of  iNOS  resulted  in  the  highest  increase  in  proliferation  rate  in  HUVECs. 
Subsequently, NOS inhibition was studied for EPCs too.  
Analogously to HUVECs, generic and iNOS specific inhibition resulted in higher proliferative 
capacity of treated cells.  iNOS is the NOS isoform that produces the highest levels if NO. 
Thus, its inhibition may attenuate the apopotic function that elevated levels of NO have.
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Fig. 24. Viability assay of HUVECs treated with NOS inhibitors.[L-NAME (1 mM),  L-NIL (100µM) and  
L-NIO (10 µM)]. At day 10, the increase of proliferative rate for cells treated with L-NAME and L-NIL is 
significantly different. CTRL vs NAME, P<0.05, CTRL vs NIL, P<0.005. 
Fig. 25. Effects of NOS inhibition on EPC proliferation. .[L-NAME (1 mM),  L-NIL (100µM) and  L-
NIO (10 µM)]. At day 10 increase of proliferation for L-NAME and L-NIL treated cells was significant. 
Ctrl s L-NAME, P<0.05, CTRL vs L-NIL, P<0.05.
NO and differentiation
In order to investigate the role of NO on EPC differentiation, mononuclear cells were cultured 
at the presence of NOS inhibitors. 
According  to  morphological  characterization,  no  significant  changes  were  observed  in  the 
number of spindle-shaped and attaching cells.
Cells  cultured  with  NOS  inhibitors  were  assessed  for  the  double  characterization  with 
DilacLDL  uptake  and UEA-FITC binding.  No significant  differences emerged in  terms of 
differentiation.
 
NO and angiogenesis
Cells were cultured with NOS inhibitors, and at day 14 th vasculogenesis ability was tested. 
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Fig. 26. Percentage of AT cells in mononuclear 
cells cultured with NOS inhibitors. Cells were 
cultured for 10 days in presence of NOS 
inhibitors and the number of differentiating AT 
cells was calculated. [L-NAME (1 mM),  L-NIL 
(100µM) and  L-NIO (10 µM)] 
Fig. 27. Characterization of EPCs treated with NOS inhibitors .[L-NAME (1 mM),  L-NIL (100µM) and 
 L-NIO (10 µM)] 
  
Apparently, incorporation of EPCs in newly formed structures was not reduced by NAME 
pretreatement. Otherwise, L-NIL seems to be more effective in reducing EPC incorporation 
new  vessels  created  by  HUVECs,.  Analogously,  L-NIO  pretreatment  reduced  EPC 
incorporation, but in a smaller rate compared to L-NIL pretreatment.
The  inhibition  of  NO production  was  not  limited  to  the  use  of  NOS inhibitors.  A novel 
technique has been adopted in order to achieve a better NOS inhibition. siRNA techniques 
specifically interact with mRNA coding for the target product, allowing to obtain an efficient 
inhibition. 
At day 7 of culture silenced EPCs were characterised by Dil-AcLDL uptake and UEA-FITC 
binding. Under inverted light fluorescence microscopy, it  was observed a decreased rate of 
cells positive to AcLDL uptake.  
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Fig. 28. Vasculogenesis assay of EPCs treated with NOS inhibitors. 1a,b: cells treated with L-NAME (1 
mM); 2a,b: cells treated with L-NIL (100µM); 3a,b: cells treated with L-NIO (10 µM).  
Fig. 29. Effectiveness of 
iNOS mRNA silencing. In 
this graph two concentrations 
of siRNA are compared. As 
negative control it was used 
luciferase siRNA. Increment 
of iNOS expression could be 
due to the treatment with the 
liposomial Transfection 
Reagent.  
 
 Nadph oxidase
Given the inflluence of ROS on NO metabolism, it was studied the expression of Nox isoforms 
by real time PCR techniques.  Endothelial cells express all  the phagocytic NADPH oxidase 
subunits, including Nox1, Nox2 and Nox4.
EPCs showed to express both Nox1 and Nox2 at higher rate compared to mature endothelial 
cells, such as HUVECs. On the contrary, Nox4 mRNA levels, which is typically expressed in 
endothelial cells, were lower in the EPCs than in HUVECs.
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Fig. 30. Characterization by Dil-AcLDL 
uptake and UEA-FITC binding of EPCs 
silenced with iNOS siRNA.
5/100: 5 µL of Transfection Reagent and 
100 pmol/mL of siRNA.
10/50: 10 µL of Transfection Reagent and 
50 pmol/mL of siRNA.  
Fig. 31. Expression of Nox1 in EPCs under differentiating condition, control EPCs (ctr), and HUVECs. 
Values are expressed relative to human megakaryocyte cell line B1647. 
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Fig. 32. Expression of Nox2 in EPCs under differentiating condition, control EPCs (ctr), and 
HUVECs. Values are expressed relative to human megakaryocyte cell line B1647.
Fig. 33. Expression of 
Nox4 in EPCs under 
differentiating condition 
and HUVECs. Values are 
expressed relative to 
human megakaryocyte cell 
line B1647.
Aim II: EPCs and hyperglycaemia
Being hyperglycaemia a leading cause of endothelium dysfunction in diabetes, the effects of 
glucose on EPCs were studied. To this end,  EPCs were cultured in normal glucose medium, 
and in medium with the addition of glucose, with a final concentration of glucose 22 mM,  and 
of mannitol, 16,5 mM. 
Firstly, it was studied the proliferation of EPCs under the different culture conditions. High 
glucose  levels  effect  cell  proliferation,  as  well  as  hyperosmolarity.  Secondly,  it  was 
investigated whether higher glucose concentration could influence EPC differentiation or not. 
Cells were cultured under previously described conditions and the number of AT cells was 
measured.
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Fig. 34. MTT test for viability.  Cells 
were cultured for 10 days under two 
different concentrations of glucose (5.5 
mM and 22 mM) and at 5.5 mM glucose 
and 16.5 Mannitol, so that to have the 
same osmolarity of hyperglycamic 
solution.   
Fig. 35. Number of AT cells in EPC 
population. Cells cultured in 
hyperglycaemic medium presented a 
lower proliferative potential, 
confirming data obtained with MTT, 
and a lower number of AT cells 
compared to control.  
Effects of Glucose on NOS Expression
Since  the  NO  is  a  key  regulator  of  EPC  function,  it  has  been  investigated  if  a  lower 
proliferation was associated with a change in NOS expression. 
As  resulted  from data  obtained  by  real  time-PCR,  high  glucose  concentration  induced  an 
enhanced expression of iNOS, eNOS and nNOS. Higher glucose concentration are known to 
enhance  the  expression  if  iNOS,  causing  an  impaired  response  to  insulin.  Though  eNOS 
expression seems to be higher compared to controls, experimental data suggest an impaired 
function of this enzyme. 
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Fig. 36. Expression of iNOS mRNA after glucose conditioning. Values are expressed relative to HUVECs.
Fig. 37. Expression of eNOS mRNA after glucose conditioning. Values are expressed relative to HUVECs.
Fig. 38. Expression of nNOS. Values are 
expressed relative to HUVECs.
Aim III: Study of EPCs in Patients with PAD and Diabetes
The third part of this study was dedicated to the characterization of the EPCs in patients with 
PAD and diabetes.  A preliminar  distinction of  patient  vascular  situation was given by the 
number of circulating endothelial  cells (CECs). In fact,  an elevated number of CECs is an 
index of  vascular damage. 
It was possible to distinguish to subpopulation in diabetic cohort.  One group had an elevated 
number of CECs, compared to the other group of diabetics and to PAD patients. In the end, all 
patients showed a at least 2-fold higher number of CECs compared to heathy subject.
Another  parameter  was  the  number  of  mononuclear  cells  isolated  from  peripheral  blood 
samples. 
 
Those patients belonging to group A presented a lower number of MNCs, indicating that, even 
if the number of CECs indicated a vascular damage, vascular repair is impaired. 
66
**
***
Fig. 39. Number of CECs in peripheral blood samples in patient with peripheral arterial disease and diabetes. 
Measure was effected by cytofluorimetric analysis. Diab A: group of diabetic cohort with elevated CEC 
number. Diab B: group of patient with CEC number comparable to that of PAD patients. Diab A vs Ctrl, 
P<0.0005; Diab A vs Diab B, P<0.005. 
Fig. 40. Number of isolated MNCs per mL of blood. PAD vs Ctrl, P<0.0005.    
Characterization of EPCs
Cells  were  cultured  under  differentiating conditions  and  observed  under  an  inverted  light 
microscope.
 
 
 
It was possible to distinguish two groups of patients, one which had good proliferative ability 
and another one who poorly proliferated. The less proliferative group, since now on called 
group A, corresponded to those diabetic patients with high levels of CECs and low levels of 
MNCs and to PAD patients. The other one, since now on called group B, corresponded to 
diabetic patients with low levels of CECs. 
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Fig. 41. Endothelial progenitor cells at different time of culture. a) day 3; b) day 7; c) day 10. Cells of 1a, b, 
and c present good proliferation, while Cells of 2a, b, and c are less proliferative 
1a 1b
1c
2a 2b 2c
Fig. 42. Proliferation of cells 
isolated from patient 
peripheral blood. Cells can be 
divided into two groups: one 
group with low proliferative 
capacity, group A, and a 
group with normal 
proliferative capacity, group 
B. Cells from healthy subjects 
were considered as controls. 
Group A day 7 and 10 vs Ctrl 
day 10: P<0.0005. Group B 
day 10 vs Ctrl day 10: P<0.05 
Also the test of viability, the MTT assay, confirmed this preliminary distinction of patients into 
two different group. 
By observing the number of AT cells, it emerged that, although cells belonging to group A 
were less proliferative, their differentiation ability was not altered. Characterization by Dil-
AcLDL uptake and UEA-FITC binding further confirmed this data. 
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Fig. 44. Characterization of 
EPCs belonging to the 
distinguished groups. No 
significant differences were 
observed between group A and 
group B.  
Fig. 43. Number of AT cells. Group A, 
which presented a low MNC number, and 
a high CEC number, confirmed to have a 
low proliferative potential, albeit a good 
differentiation rate was assessed. Group 
B, instead, presented a normal 
proliferative capacity and high 
differentiation rate.  
Vasculogenec potential
As resulted from the in vitro angiogenesis model, the two populations showed different ability 
to participate to tube formation. The first group presented a low incorporation rate in the new 
capillary-like  structures  formed  by  HUVECs,  while  the  second  group  showed  a  higher 
vasculogenic potential.  
                
              
Since EPCs belonging to group B had shown no significant impairment in participation to 
vasculogenesis, it was tested whether they could be able to autonomously form capillary-like 
structures. If seeded at 3-fold higher concentration, they gave origin to tube formation.     
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Fig. 45. Participation of EPCs to new vessel formation. EPCs from group A (a) and from group B (b) were 
plated together with HUVECs on Matrigel matrix. Group A showed a limited capacity to incorporate to 
newly formed structures.
Fig. 46. Angiogenic capacity of diabetic 
EPCs. Cells were seeded at 30000 
cell/well on matrigel coated plates and 
their vasculogenic ability was assessed.
As hypothesised, the cells of group B were 
able to form approssimative capillary like 
structures as well as normal EPCs do.
NOS Expression
The  following  step  was  to  understand  if  there  was  a  correlation  between  the  reduced 
proliferative and angiogenic potential and the expression of NOS isoforms.
As regards eNOS mRNA expression in the studied cohorts, it did not emerged a significant 
variation in its levels in EPCs. However a slight increase was observed in diabetic patients with 
normal proliferation, thus probably allowing cells to be more functional.   On the contrary, 
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Fig. 47. Expression of eNOS 
mRNA in patients with PAD and 
in diabetic patients with low (A) 
and normal (B) proliferative 
capacity.
Fig. 48. Expression of iNOS 
mRNA in patients with PAD and 
in diabetic patients with low (A) 
and normal (B) proliferative 
capacity.
Fig. 49. Expression of nNOS 
mRNA in patients with PAD and 
in diabetic patients with low and 
normal proliferative capacity.
diabetic  patients  with  low  proliferative  capacity  presented  a  significant  increase  in  iNOS 
expression, much more higher than the other populations considered in this study. 
Moreover, both groups of diabetic patients  did not express the neuronal isoform. Likewise 
other cell populations in diabetic patients, EPCs showed an impairment in nNOS expression.
Modulation of the NADPH Oxidase Expression 
Finally, it was investigated whether the endothelium dysfunction could be not only due to an 
impaired NOS expression, but also to oxidative stress. 
 
Data  indicated  that  Nox1 levels  were  extremely high in  patients  affected by  PAD, and in 
particular, in diabetic ones. As a result,  EPC dysfunction could be caused by an increased 
oxidative stress and consequent impairment of NOS production, because of NOS uncoupling. 
Moreover, Nox2 is less expressed in non-diabetic patients. Nox2 is known to be involved in 
VEGF-signalling,  and  subsequent  VEGF-induced  neovascularization.  Hence  low  levels  of 
Nox2 may be associated to a reduced vascularization.
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Fig. 50. Expression of Nox isoforms, Nox1 and Nox2 in diabetic and non diabetic patients affected by PAD 
(n=2).Nox1 graph: Diabetic vs control P<0.0005, Non-diabetic P<0.005. Nox2 graph: Non-diabetic vs 
control P<0.005.
Chapter 10
Discussion
Changes  in  human  lifestyle  and  healthcare  have  resulted  in  a  dramatic  increase  in  the 
prevalence of cardiovascular disease. Atherosclerosis-related vascular disease is responsible for 
half the deaths in Europe and the growing population of diabetic patients is particularly prone 
to  occlusion of  arteries  and suffers a  more  complicated clinical  outcome after  myocardial 
infarction or stroke compared with non-diabetics (129). 
Initially pharmacological treatement was considered the only instrument to alleviate symptoms. 
Afterward, the advent of mechanical revascularization by angioplasty improved the survival 
rate and life quality of patients. However, not all patients can undergo this kind of therapy. 
Thereby, it was essential to find an alternative method. 
In the last decade a novel concept arose, that improvement in perfusion can be achieved by 
new vessel formation. This new approach postulate a lack of or an insensitivity to angiogenic 
factors, thus, supplementation with cytokines would counteract the deficiency of endogenous 
growth  factors  typical  of  vascular  disease.  However,  the  increasing  evidence  that 
neovascularization in adults is not uniquely dependent on resident ECs but also involves bone 
marrow derived EPCs, suggested the use of these cells for therapeutic use. In fact, therapeutic 
vasculogenesis, which is a cell-based version of biological revascularization, postulates that the 
transplantation of endothelial progenitor cells can enhance native regenerative mechanisms and 
thereby produce clinically valuable improvement in blood flow. EPCs can be isolated from 
different  sources.  However,  isolation  from  peripheral  blood  is  less  invasive,  so  that 
hematopoietic cells can be harvested and readministrated  for autologous transplantation  .
This study was focused on better understanding the vasculogenic potential of EPCs isolated 
from blood, their differentiative and proliferative capacity with respect to NO signalling and 
glycaemia, and to a pathological condition, such as peripheral arterial disease.
The hematopoietic population was isolated and cultured under differentiating conditions. After 
few days it was possible to observe spindle-shaped and attaching cells, also referred to as AT 
cells. This is already considered an endothelial-like morphology. Moreover, these cells tended 
to form clusters and subsequently, to assume a cobblestone aspect, that is very similar to that of 
mature endothelial cells, such as HUVECs. 
Being the morphological characterization not sufficient to define this population, the adherent 
cells  were  characterised  by  a  double  staining,  the  Dil-acetylated  LDL uptake  and  UEA-I 
binding.  After one week, about 70% of cells was positive to both markers, and this value 
increased throughout time. 
Once  differentiation toward  an  endothelial  phenotype  was  assessed,  the  next  step  was  to 
determine whether these cells were able to form capillary-like structures. If seeded on Matrigel 
membrane, EPCs were not able to do tube formation ex novo. They were only able to give 
origin  to  rough  vascular  structures.  On  the  contrary,  when  plated  together  with  mature 
endothelial cells, EPCs showed ability to partecipate to vasculogenesis. In fact, labelled EPCs 
were visibly incorporated into the newly formed structures. In the end, this would be more 
similar to the in vivo situation. Actually EPCs are known to home to sites of neovascularization 
sites and work in concert with existing endothelial cells so that to form vessels.
Increasing evidence demonstrated the key role of NO in angiogenesis and vasculogenesis (95). 
On  the  basis  of  these  data,  it  was  examined  the  metabolism of  NO in  EPCs.  By  use  of 
fluorescent probe DAF-2DA, it emerged that these cells produced NO. In mature endothelial 
cells, NO effects angiogenic process via transduction pathway VEGF-eNOS-NO and eNOS is 
considered the principal NOS isoform involved in vasculogenesis (73). Hence, the expression 
of  this  isoform in  EPCs  was  investigated.  Both  eNOS protein,  assessed  by  Western Blot 
analysis, and mRNA, assessed by qPCR, resulted to be much lower compared to the expression 
of this enzyme in HUVECs. Also the other constitutive isoform, nNOS, was less expressed 
than in HUVECs. On the contrary, the trend of iNOS was completely different. iNOS protein 
was  detectable  by  Western Blot,  and  its  mRNA values  were  2-3fold  higher  than  those  in 
HUVECs. 
In  order  to  understand  which  was,  actually,  the  principal  isoform  responsible  for  NO 
production in EPCs, two weeks cultured cells were pretreated with NOS inhibitors, the generic 
inhibitor L-NAME, the iNOS specific one L-NIL, and the eNOS specific one L-NIO and the 
NO production was measured by using DAF-2DA. Results seemed to confirm the previous 
data. In fact, L-NIL caused the highest inhibition of NO production. Although L-NAME was a 
generic inhibitor and was supposed to strongly inhibit NO production, it was less effective than 
L-NIL. It has to be considered that, finally, L-NAME presents a higher affinity for constitutive 
isoforms.  The lesser  inhibitory  power  registered  for  L-NAME would  support  the  previous 
findings  of  a  lower  expression  of  constitutive  NOS isoforms  in  EPCs,  in  comparison  to 
inducible NOS. 
Then, the following step was to assess the role of the three isoforms in EPC homeostasis, as 
regards proliferation, differentiation and vasculogenesis.  By treating cells with NOS inhibitors 
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for two weeks, it was observed an increase in the proliferative rate for cells cultured with L-
NAME, and, in particular, for those cultured with L-NIL. The positive effect of NO depletion 
on proliferation could be explained by the dual role of NO, either apoptotic or not. Highest 
levels of NO are, in fact, associated with an enhanced cell apoptosis.
iNOS inhibition in  EPCs also  exhibited a  reduction  in vasculogenic  ability  of  these  cells. 
Matrigel assay was performed on EPCs pretreated with NOS inhibitors and cells inhibited with 
L-NIL showed to be less incorporated in newly capillary-like structures. In their work, Mayr 
and  coworkers  had  actually  reported  a  central  role  of  inducible  NOS  in  vein  graft 
reendothelialization  (101).  Moreover,  it  was  investigated  if  iNOS  silencing  affected  EPC 
differentiation. Cells treated with iNOS siRNA exhibited a lower Dil-acetylated LDL uptake, 
thus reducing the rate of cells positive to double staining. 
It is known that NO inhibition can also be caused by enhanced ROS expression. Hence, it was 
studied  the  expression  of  NADPH oxidase  complexes  in  physiological  conditions.  It  was 
evaluated the expression of Nox1, Nox2 and Nox4. The last two ones represent the major 
source of ROS in endothelial cells, while Nox1 is principally expressed in phagocytic cells. 
EPCs presented a higher expression of Nox1 and Nox2, compared to mature endothelial cells. 
This can be considered as a consequence of the macrophagic origin of EPCs. On the contrary, 
Nox4 was less expressed in EPCs compared to HUVECs. Being Nox4 highly expressed in 
endothelium, its lower levels in EPCs were a further evidence of progressing but not concluded 
EPC differentiation toward an endothelial phenotype. 
Since the final aim of this research was the study of EPCs isolated from patients affected by 
PAD and diabetes,  it  was  investigated the effect of  the most  damaging factor  in diabetes: 
hyperglycaemia.  Control  cells,  isolated  from  healthy  volunteers,  were  cultured  under 
hyperglycaemic conditions  (22  mM glucose)  and  under  hyperosmotic  conditions  (5.5  mM 
glucose and 16.5 mM mannitol). Cells under hyperglycaemic conditions exhibited a reduced 
proliferation,  compared  to  controls.  Hyperosmosis  also  induced  a  decrease  in  EPC 
proliferation, but less than high glucose concentration did. Analogously, also differentiation 
was  altered.  Hyperglycaemic  EPCs  showed  a  lower  number  of  adherent  cells,  and  most 
importantly, a lower percentage of AT cells.  As regards NOS expression, cells exposed to high 
glucose concentrations had an increase in iNOS expression, and also of the other constitutive 
isoforms. 
EPCs isolated from patients affected by PAD and diabetes also showed an impairment in cell 
proliferation, although it has to be done a distinction among the different patients. 
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A preliminar characterization of vascular situation of these patients was given by the number of 
circulating  endothelial  cells.  It  is  widely  recognized  that  an  increased  CEC  number  is 
associated  with  a  more  serious  vascular  damage.  Non-diabetic  cohort  affected  by  PAD 
presented high CEC number in peripheral blood compared to control cells,  and showed an 
impaired proliferation. On the contrary, diabetic cohort could be classified into two groups. 
One group had a very high number of CECs and  a poor proliferative ability.  The other group 
had a CEC number similar to that  of non-diabetic PAD patients,  but  presented quite good 
proliferative ability. The dual functionality of diabetic patients could be referable to the number 
of mononuclear cells, and thus of EPCs, isolated from patient peripheral blood. In fact, patients 
belonging to the first group had a lower number of MNCs compared to patients belonging to 
the second group. However, PAD patients showed a very high number of MNCs, but that 
resulted unable to adequately proliferate.      
With respect to EPC differentiation, it  was not detected any significant difference between 
patients with good and those with bad proliferative capacity. Although, when it was tested their 
vasculogenic potential, the first ones showed a relative good rate of incorporation into new 
structures  formed by  HUVECs,  and even demonstrated to be  able  to  form approssimative 
vessels ex novo, as well as EPCs from healthy subjects do. Patients with low proliferative 
capacity exhibited low incorporation rate, instead. 
Concerning NOS mRNA expression, eNOS was not significantly different among examined 
patients. Only a slight increase was observed in diabetic patients with good proliferation rate. 
Also iNOS mRNA expression was similar to that of controls, except for the diabetic patients 
with less functional EPCs. In this group iNOS expression was extremely high. Probably in 
these cells with increased iNOS levels could result in too high NO release, causing its apoptotic 
effects  rather  than  positive  for  reendothelialization.  Finally, nNOS was  not  or  too  poorly 
expressed in diabetic patients. Studies in other cell types have already evidenced an impairment 
in nNOS in diabetic patients, being this enzyme important in insulin-response to arginin. In 
animal model, eNOS and nNOS deficiency causes insulin resistance in skeletal muscle cells, 
while induction of iNOS is associated with impaired insulin-stimulated muscle glucose uptake 
(130).
Finally, being atherosclerosis associated to inflammation and increased oxidative stress, it was 
investigated the expression of NADPH oxidases, Nox1 and Nox2, in the two groups. Both 
diabetic and  nondiabetic patients showed a high enhancement of Nox1 levels compared to 
controls. Nox1 is not constitutively activated in endothelial cells, thus, in atherosclerosis there 
are stimuli which cause the translocation of cytosolic subunits and subsequent Nox1 activation. 
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On the contrary, Nox2 resulted to be less expressed compared to controls.  Hence, a lower 
response to the angiogenic factor VEGF could occur as a consequence of the reduction of 
Nox2 mRNA expression.  
In conclusion, NO is confirmed to play a crucial role in EPC ability to differentiate and to take 
part in vasculogenesis. Moreover, the NOS activity seems to be involved in cellular response to 
glucose and insulin metabolism, as registered for diabetic patient, and especially nNOS. Albeit 
non-diabetic patients did not present a significant difference in eNOS and iNOS expression, it 
has not be excluded an impairment of enzymatic function, due to increased Nox1 expression 
and subsequent enhanced ROS production.
Since  a  group  of  patients  presented  a  quite  normal  EPC  function  in  vitro,  it  has  to  be 
hypothesised the presence of negatively conditioning factors in vivo.  Hence, concerning the 
use  of  autologous  transplantation  of  EPCs  for  reendothelization  of  vein  graft,  it  becomes 
essential to find preconditioning substances which  would counteract the endogenous negative 
factors. NO could considered an elegible candidate for this. 
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